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ABSTRACT 
 
 
 In an effort to combat the global Tuberculosis pandemic, Dr.Richard E. Lee and 
his group at St.Jude Children’s Research Hospital designed a novel series of anti-
tuberculosis agents, spectinamides – semi-synthetic analogs of spectinomycin. 
Spectinamides are a potent inhibitor of mycobacterial ribosomes and overcomes efflux 
mediated drug resistance in M. tb. 
 
 Spectinamides have shown an excellent in vitro activity, which makes them well 
suited for further lead optimization and preclinical development. We hypothesized that 
through pharmacokinetic (PK) and pharmacodynamics (PD) model-based dosing 
optimization studies, we could strategically guide the selection and refinement of more 
potent and effective anti-TB spectinamides. 
 
 Biopharmaceutical in vitro screening demonstrated that spectinamides in general 
have low plasma protein binding and are stable against hepatic microsomal metabolism. 
In vivo pharmacokinetic studies in rats revealed that the kidneys are the major route of 
elimination for spectinamides in their unchanged form. Radiolabeled biodistribution 
studies showed 84.7% of radioactivity accumulated 70% in urine, 12.6% in feces, and the 
remainder in the blood and other major organs. The unaccounted for residual 15.3% 
likely distributed into the epidermis and other surface tissue. In multiple-dose 
accumulation studies, the Cmax of radiolabeled compound after the 1st dose and the 8th 
dose of twice-daily dosing regimen was similar: 3.39μCi/mL and 3.55μCi/mL, suggesting 
no relevant accumulation of parent drug and metabolites. The concentration of 
radiolabeled compound was three times more in lungs and spleen as compared to whole 
blood, suggesting good tissue penetration. Macrophage uptake studies showed that Lee 
1329, Lee1445 and Lee 1599 had significantly higher macrophage uptake than 
spectinomycin and streptomycin. Lee 1329 showed 6-fold and 2.2-fold higher uptake 
than streptomycin and spectinomycin, respectively. 
 
 Based on the results of the in vitro experiments and preliminary PK/PD studies in 
rats, Lee 1599 was selected as the lead candidate compound. To predict PK/PD indices of 
anti-microbial efficacy, we performed model-based dosing optimization studies with Lee 
1599. We used an in vitro PK/PD model system to simulate the rat PK conditions while 
evaluating antibacterial activities to predict effective dosing regimens for further in vivo 
efficacy studies. Our results have shown that Lee 1599 exhibits dose-dependent 
bactericidal effect. Lee 1599 showed up to 4-log reductions in bacterial counts at 100mg 
QD dosing. The PK/PD indices demonstrated that Lee 1599 elicits a concentration- and 
time-dependent killing with AUC/MIC as the optimal index. The model was put through 
numerical simulations to predict the effect of Lee 1599 in mice at various dosing 
regimens. The in vitro PK/PD simulated profile has suggested that high doses with 
frequent dosing intervals may demonstrate optimum in vivo efficacy. 
 
 Consequently, we aimed to determine the pharmacodynamic interaction between 
Lee 1599 and existing anti-tuberculosis agent. We selected rifampicin as a model 
 vii 
compound and applied a parametric approach to quantitatively assess the 
pharmacodynamic drug interaction between Lee 1599 and rifampicin. The three 
dimensional surface response assay demonstrated that there is an additive effect between 
both the agents as opposed to the conventional checkerboard assay, which suggested 
synergism between these agents. The results of surface response assay were validated 
using an in vitro PK/PD model for combination agents and in vivo efficacy trials, which 
showed an additive effect between Lee 1599 and rifampicin. Thus, quantitative assays 
such as the surface response assay seem to provide more reliable information on 
pharmacodynamic interactions as opposed to qualitative methods such as checkerboard 
assay.  
 
 In conclusion, we have successfully supported the further development of 
spectinamides using a pharmacometric approach. We have identified a lead candidate 
compound Lee 1599 using an iterative PK/PD approach for its pre-clinical drug 
development. The application of PK/PD knowledge is essential for translating the in vitro 
screening assay findings to the in vivo stage, thus accelerating the drug development 
process. The results of the above studies can be used as a roadmap for the optimization of 
anti-infective agents in the early drug discovery and pre-clinical developmental phase. 
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CHAPTER 1.    APPLICATION OF PHARMACOMETRICS IN THE CLINICAL 
DRUG DEVELOPMENT OF ANTI-INFECTIVES* 
 
 
Introduction 
 
 With the increased emergence of anti-infective resistance in recent years, much 
focus has recently been drawn to the development of new anti-infectives and the 
optimization of treatment regimens and combination therapies for established 
antimicrobials. In this context, the field of pharmacometrics using quantitative numerical 
modeling and simulation techniques has in recent years emerged as an invaluable tool in 
the pharmaceutical industry, academia and regulatory agencies to facilitate the integration 
of preclinical and clinical development data and to provide a scientifically based 
framework for rationale dosage regimen design and treatment optimization. The 
following chapter highlights the usefulness of pharmacometric analyses in anti-infective 
drug development and applied pharmacotherapy with select examples. 
 
 
Pharmacometrics in Anti-infective Drug Development  
 
 The increased emergence of multidrug resistant (MDR) microbial strains in recent 
years and the resulting complications in the clinical care for infected patients is a strong 
reminder for the urgent need to develop new anti-infective agents. As the battle against 
drug-resistant microorganisms rages on in clinical centers around the globe, the 
development of novel single agent and combination therapies against microbial infections 
has challenged research scientists in the pharmaceutical industry and academia as well as 
clinicians and other healthcare providers to seek a multi-disciplinary approach; one that 
encompasses microbiology, clinical expertise, and drug development sciences. 
Pharmacometrics has in this context arisen as a formidable tool to bridge and link 
between key concepts in these disciplines and to provide a rationale, scientific framework 
throughout the drug development continuum as well as in clinical applications [1, 2]. 
There are case studies which suggest that basing optimization of treatment on 
pharmacometric assessments improves the risk-management of MDR pathogens in the 
clinical realm by minimizing the failures and mistakes associated with inappropriate or 
careless use of antibiotic therapies [3, 4]. 
 
 Pharmacometrics is the scientific discipline that uses mathematical models based 
on biology, pharmacology, physiology, and disease for quantifying the interactions 
between drugs and patients (Figure 1-1). Data and information from various sources are 
bridged together and quantitatively related to each other. Computer-based modeling and 
simulation of pharmacokinetic (PK) and pharmacodynamic (PD) data (denoted as PK/PD 
M&S) usually forms the basis for a pharmacometric analysis, but is frequently 
-------------------- 
* Adapted with permission. Ashit Trivedi, Richard E. Lee, and Bernd Meibohm. (2013). 
Applications of pharmacometrics in the clinical development and pharmacotherapy of 
anti-infectives. Expert Review of Clinical Pharmacology, 6(2), 159-170. 
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Figure 1-1. Illustration of interplay of pharmacology, microbiology, physiology, 
disease and their association with pharmacometric evaluations in the clinical 
development and application of anti-infectives. 
 3 
supplemented by models characterizing important other aspects of drug efficacy and/or 
safety in a given situation, such as disease progression, adherence to therapy or bacterial 
growth and infection [5]. PD measures used in pharmacometrics are frequently 
biomarkers, but can also be surrogate endpoints or clinical endpoints. 
 
 Pharmacometrics is aimed at establishing models that provide guidance and 
decision support in drug development such as trials design, efficacy comparisons, dosage 
regimen optimization and endpoint analysis, but also in supporting regulatory decisions 
and improving clinical care in specific patient populations [6, 7]. Its purpose is thereby to 
reduce cost and shorten development time by optimizing the clinical assessment of 
efficacy and safety. 
 
 An increased application of pharmacometric methodologies in drug development 
and applied pharmacotherapy has in the last decade been strongly promoted by industry, 
academia and especially regulatory agencies, with specific emphasis from the U.S. Food 
and Drug Administration [8, 9]. Pharmacometrics has been extensively used in the 
development and application of novel antibiotics [10-12]. In addition, increasing 
emphasis is more recently being placed on dose selection of approved antibiotics already 
in clinical use, with heavy reliance on quantitative benefit-risk evaluations [13]. 
 
 This chapter aims to provide an overview on the usefulness and utility of 
pharmacometrics and in specific modeling and simulation approaches (M&S) in anti-
infective drug development and clinical application (Table 1-1), and will highlight these 
in examples on the application of M&S approaches in three specific areas: 
 
1. The determination of PK/PD indices and susceptibility breakpoints indicative of 
anti-microbial activity in clinical populations. 
 
2. The development of optimal dosing regimens for effective and safe anti-microbial 
therapy in both general and specialized population groups, such as pediatric 
patients. 
 
3. The optimization of key attributes of study design in clinical development and 
postmarketing evaluations. 
 
 
Prerequisites for the Application of Pharmacometrics  
 
 One of the major prerequisites for the application of M&S in clinical drug 
development and applied pharmacotherapy is the availability of a mathematical 
framework that captures the dose-exposure relationship for the antibiotic in relevant 
tissues of interest (i.e. the plasma and tissue pharmacokinetics), the growth characteristics 
of the pathogen and its relevant subpopulations in the in vivo environment 
(microbiology), and the dynamic interplay between pathogen and antibiotic exposure 
with regard to pathogen survival, death, latency or resistance (pharmacodynamics).  
 4 
Table 1-1. Examples of the application of pharmacometrics analyses for anti-infectives. 
 
Drug Organism Disease Target site 
Objective for 
performing 
pharmacometrics 
analysis 
Outcome Population Ref. 
Biapenem Gram positive 
and gram 
negative 
anaerobes 
Continuous 
venovenous 
hemodiafiltration 
(CVVHDF) 
Plasma and 
filtrate-
dialysate 
Determine 
appropriate dosage 
recommendation 
for patients on 
CVVHDF 
300mg BID, 
intravenous (2 h 
infusion) 
Adult  Japanese 
(mean 65.1 yr), 
N=7 
[14] 
Cefditoren Streptococcus 
pneumoniae 
Lower respiratory 
tract infections 
Plasma and 
BAL 
PD profiling & 
determining PTA 
(Dose: 400mg QD, 
oral) 
PTA with 33% 
T>MIC is <80% for 
MIC = 0.06mg/L 
Adult Caucasian 
(35-78 yr) N=24 
[15] 
Cefepime 
 
Streptococcus 
pneumoniae 
Extracerebral 
infections 
Serum and 
CSF 
PD profiling & 
determining PTA 
(2g BID, 0.5h IV 
infusion) 
PTA in CSF with 
50% T>MIC is 
91.8%, 100% 
T>MIC is 82% 
Adult females 
(mean 58.9 yr) 
N=7 
[16] 
Ceftobiprole 
 
Staphylococcus 
aureus 
Staphylococcal 
pneumonia 
ELF, serum, 
BAL 
PD profiling & 
determining PTA 
(500mg, TID, 2h 
IV infusion) 
PTA with T>MIC is 
15% for 1-log10 
CFU/g reduction; 
25% for 2-log10 
CFU/g reduction 
Adults (>18 yr)  
N=25 
[17] 
Staphylococcus 
aureus,  
Streptococcus 
pneumoniae 
Nosocomial 
pneumonia 
Skin, Plasma PD profiling & 
determining PTA 
& renal dose 
adjustments (500 
mg BID, 1h 
infusion; 500mg 
TID, 2h infusion) 
With 500mg, BID: 
PTA of 30% and 
50% T>MIC 
exceeded 90%. With 
500 
\mg, TID: PTA of 
40% and 60% 
T>MIC exceeded 
90%. 
500mg, BID is 
optimal dose for 
CLCr ≤ 50mL/min 
Adults, N=150 [18] 
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Table 1-1. (Continued). 
 
Drug Organism Disease Target site 
Objective for 
performing 
pharmacometrics 
analysis 
Outcome Population Ref. 
Ceftriaxone Streptococcus 
pneumoniae 
Extracerebral 
infections 
CSF PD profiling & 
determining PTA 
(2g BID, 0.5h 
infusion) 
PTA is 76% for 
50% T>MIC in 
CSF; 
PTA is 65% for 
100% T>MIC in 
CSF 
Adult females 
(mean age 58.9 
yr) N=7 
[16] 
Garenoxacin 
 
Streptococcus 
pneumoniae 
Community-
acquired 
pneumonia (CAP) 
Serum, ELF Evaluate exposure-
response 
relationship by 
population PK/PD 
fAUC0-24/ MIC90 > 
200 
400mg QD, Oral 
dosing is safe and 
adequate for 
efficacy 
Adults (?18 yr) 
N=580 
[19, 20] 
Streptococcus 
pneumonia, 
Staphylococcus 
aureus, 
Klebsiella 
pneumonia, 
Moraxella 
catarrhalis, 
Haemophilus 
influenzae 
Pneumonia, 
secondary 
infection of 
chronic respiratory 
diseases, 
bronchitis, 
sinusitis,  
otis media, 
laryngopharyngitis, 
tonsillitis 
 Determine PTA in 
serum and ELF 
PTA > 95% for 
fAUC0-24/ MIC90 is 
100 (serum) and 
120 (ELF) 
Adult Japanese 
(?18 yr) N=136 
[21] 
Gatifloxacin Streptococcus 
pneumoniae 
Community-
acquired 
pneumonia (CAP) 
N/A PD profiling & 
determining PTA 
at 400mg QD, oral 
(young) and 200 
mg QD, oral 
(elderly) 
PTA for AUC0-
24/MICall ≥ 30 is 
92.3% in young; 
91.4% in elderly 
 
Adults 
Young (<65 yr) 
Elderly (>65 yr) 
N=183 
[22] 
Gemifloxacin Streptococcus 
pneumoniae 
Community-
acquired 
pneumonia (CAP) 
Serum, ELF PD profiling & 
PTA in serum and 
ELF 
(320mg QD, oral) 
PTA (>95%, or 
>99% [23]) for 
fAUC0-24/MIC90 is 
100 (ELF) and 
78.3-88 (Serum) 
N/A [20, 23] 
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Table 1-1. (Continued). 
 
Drug Organism Disease Target site 
Objective for 
performing 
pharmacometrics 
analysis 
Outcome Population Ref. 
 
Levofloxacin 
 
Escherichia coli, 
Chlamydia 
Prostatitis Prostatic 
tissue 
Determine 
penetration at site 
of action (500mg 
QD) 
AUCprostrate/AUCplasma 
is 2.96 
Adult (47-94 yr) 
N=22 
[24] 
Organisms 
causing 
Pneumonia 
Nosocomial 
pneumonia 
Plasma, ELF Determine 
penetration ratio in 
ELF (500mg QD; 
750mg QD) 
AUCELF/AUCplasma is 
1.16 
Adult (> 18 yr)  
N=24 
[25] 
Metronidazole Bacteroides 
fragilis 
N/A Plasma and 
urine 
PD profiling & 
determining PTA 
at 500mg, TID; 
1000mg QD; 
1500mg QD 
PTA for AUC/MIC 
≥70 is 99% 
Adults males, 
N=18 (10 
healthy, 8 
patients) 
[26] 
Moxifloxacin Streptococcus 
pneumoniae 
Community-
acquired 
pneumonia 
(CAP) 
Serum, ELF PD profiling & 
determining PTA 
(400mg QD, 1h 
infusion) 
PTA (>95%) for 
fAUC0-24/ MIC90 is 
120 (ELF) and 78.3-
88 (Serum); 
Cmax/MIC90 >10, 
AUC/MIC90 ~ 100 
Adults (18-80 
yr) N=16 
[20, 27] 
Norvancomycin Staphylococcus 
aureus 
Gram-positive 
bacterial 
infections 
Serum PD profiling & 
prediction of CL 
estimates in 
population (400mg 
QD, intravenous) 
95% cured clinical 
outcome with AUC0-
24/MIC of 579.9 
CL=2.54(CLCr/50) in 
patients with renal 
dysfunction 
CL=6.0(Body 
Weight/60)0.52 in 
healthy subjects 
Adult, N=166 [28] 
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Table 1-1. (Continued). 
 
Drug Organism Disease Target site 
Objective for 
performing 
pharmacometrics 
analysis 
Outcome Population Ref. 
Oseltamivir and 
Oseltamivir carboxylate 
(OC) 
Influenza A 
(H1N1 virus) 
Influenza A 
and B 
Serum To determine 
dosing in neonates 
and infants 
3mg/kg, BID, Oral 
in infants 1.7mg/kg, 
BID, Oral in 
neonates 
Adult males 
N=6; 
Infants (<2 yr) 
N=43; 
Neonates (1.5-
17.5 weeks) 
N=20 
[29, 
30] 
Piperacillin/Tazobactam 
(combination) 
Escherichia 
coli, S. aureus, 
Klebsiella 
pneumonia, 
Pseudomonas 
aeruginosa, 
Bacteroides 
fragilis, 
Acinetobacter 
baumannii 
Gram-negative 
bacterial 
infections 
Serum To determine 
PK/PD parameters 
& in vivo 
effectiveness with 
doses 3.375g, 
Q4h, Q6h; 
4.5g, Q6h, Q8h 
(intravenous,0.5h 
infusion) 
T>MIC is >60% for 
all doses 
Adult males  
N=12 
[31, 
32] 
Rifampin Mycobacterium 
tuberculosis 
Tuberculosis Plasma, ELF, 
BAL, 
Alveolar 
Cells (ACs) 
Determine 
pulmonary PK/PD 
in lungs & 
evaluate 
recommended 
dose (600mg, QD, 
oral) 
Cmax/MIC ≥ 175 are 
95% (ACs), 48.8% 
(plasma), 35.9% 
(ELF); AUC0-
24/MIC ≥ 271 is 
100% (plasma); 
Higher doses (1200 
mg) required as 
pulmonary 
concentration is too 
low with 
recommended 
dosing 
Adults, N=40 [33] 
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Drug Organism Disease Target site 
Objective for 
performing 
pharmacometrics 
analysis 
Outcome Population Ref. 
Telavancin  Staphylococcus 
aureus 
Health care 
associated 
pneumonia 
Plasma and ELF To determine 
penetration in ELF 
with 10mg/kg QD 
(intravenous, 1h 
infusion) 
AUCELF/AUCplasma 
is 0.73 
Adult 
Caucasians, 
N=20 
[34] 
Vancomycin Staphylococcus 
aureus 
Ventilator-
associated 
pneumonia 
Plasma,  
Bronchoalveolar 
lavage fluid, 
ELF 
To determine 
penetration in ELF 
with 1000mg BID 
(intravenous) 
AUCELF/AUCplasma 
is 0.675 
AUC/MIC ≥ 400 
Adults (>18 
yr) 
 N=10 
[35] 
Voriconazole Candida strains N/A Plasma To investigate the 
effect of 
concomitant 
fluconazole on 
Voriconazole PK 
Coadministration 
is not 
recommended, 
Monitor for 
adverse events if 
voriconazole is 
sequentially 
administered after 
fluconazole 
Adult males 
(21-55 yr) 
N=10 
[36] 
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 Relevant PK and PD parameters may be derived from a variety of sources, 
including preclinical and clinical pharmacokinetic studies, studies assessing tissue 
concentration-time courses with techniques such as imaging or microdialysis, in vitro 
MIC data, in vitro time-kill curves, disease pathology, and microbiologic characteristics 
of the pathogen/infective agent itself [37, 38]. These data can be combined with 
knowledge about the between- and within-subject variability in relevant PK parameters 
as well as microbiologic differences among different pathogen strains. Since between-
subject variability is oftentimes a major complicating factor in drug development and 
pharmacotherapy, the potential impact of M&S approaches is usually higher the larger is 
the between-subject variability. The resulting models help identify optimal drug 
concentrations necessary to achieve at the target site to be efficacious in overcoming an 
infection (i.e. bacterial eradication) and minimizing bacterial resistance, and the 
corresponding dosing regimens that provide a high likelihood of therapeutic success in a 
specific target population [10, 39]. Once this basic framework has been established, 
additional factors including human physiological, biochemical, and genetic variability 
and differences to preclinical species that complicate the translation of preclinical results 
to the clinic and of data from controlled clinical studies to clinical practice may be 
considered and implemented in the modeling framework. 
 
 
PK/PD Indices and Susceptibility Breakpoints 
 
 Susceptibility breakpoints, or critical antimicrobial concentrations, are valuable 
parameters in assessing the degree of drug susceptibility and/or resistance to an 
antimicrobial pharmacotherapy. Breakpoints refer to antibiotic concentrations or 
exposures that separate bacterial strains where there is a high likelihood of treatment 
success from those bacteria where treatment is more likely to fail. Historically, 
pharmacokinetic exposure parameters such as the area-under-the-plasma-concentration-
time-curve (AUC) or the maximum or peak concentration (Cmax) have been the gold 
standard for monitoring drug action under the assumption that plasma concentration are 
indicative of target site concentrations and that a defined and fixed target site exposure is 
necessary for drug action. For antimicrobial pharmacotherapy, however, target site 
exposure is not sufficient to predict efficacy since the susceptibility of the microorganism 
to the target site concentration is variable among different microorganisms and strains 
and may change over time in the event of for example resistance development. 
Susceptibility of a microorganism to an antibiotic is frequently described by its minimum 
inhibitory concentration (MIC), an in vitro parameter that quantifies growth inhibition to 
a static antibiotic concentration. Combination of the pharmacodynamic parameter MIC 
with pharmacokinetic exposure parameters such as AUC or Cmax allows defining PK/PD 
indices that are hybrid parameters that integrate PK and PD information related to target 
exposure and microbial sensitivity, and can be used to derive PK/PD breakpoints. 
Dependent on the predominant mechanism of action of the antibiotic, the following three 
PK/PD indices (as shown in Figure 1-2) have been found useful in characterizing in vivo.  
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Figure 1-2. Illustration of the PK/PD indices at steady state during multiple 
dosing: (i) T>MIC: Time above MIC (ii) Cmax/MIC (iii) AUC/MIC.  
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1. T > MIC: Time T of exposure of microorganisms to plasma concentrations 
exceeding its MIC. 
 
2. Cmax/MIC: Ratio of peak plasma concentration to MIC. 
 
3. AUC/MIC: Ratio of area under plasma concentration curve to MIC. 
 
 These indices are frequently used to classify the pattern of killing activity for 
antimicrobials, concentration-dependent vs. time-dependent. Antibiotics for which T > 
MIC best describes their antimicrobial activity follow time-dependent killing with 
minimal persistent effects that requires a maximum duration of exposure above MIC for 
maximum activity. Antibiotics for which Cmax/MIC best describes their antimicrobial 
activity follow concentration-dependent killing with prolonged persistent effects that 
require a maximum peak antibiotic concentration for maximum activity. Antibiotics for 
which AUC/MIC best describes their antimicrobial activity exhibit both time-dependent 
and concentration-dependent killing with moderately persistent effects that require a 
combination of high concentration and long duration above MIC for maximum activity. 
The AUC in these indices is calculated at pharmacokinetic steady state over 24h 
(AUCss,0-24) and is usually derived from Bayesian parameter estimates from population 
PK analysis approaches.  
 
 As indicated in these relationships, the MIC is consistently used as a denominator 
or ‘normalization factor’. The integration of drug exposure (PK) and the actual drug 
activity based on microbial sensitivity (PD) allows to develop generalized breakpoints 
with which multiple drugs can be evaluated for efficacy related to both their PK and PD 
parameters [40-42]. The efficacy is the desired clinical effect that a particular drug is 
producing and is the combined effect of PK and PD and other, for example patient-
related, factors. The term ‘efficacy’ cannot be interchanged for PD.  Thus, breakpoints 
are often used as a valuable tool in drug development and applied pharmacotherapy to 
optimize dosing regimens of an antibiotic for the treatment of a specific pathogen and to 
minimize the increase of resistant strains with optimal dosing. 
 
 It should be stressed, however, that many antibiotics are bound to variable degree 
to proteins in plasma and tissue, and that only the free, unbound concentration at the 
target site is pharmacologically active and exerts the antimicrobial activity. Since MIC is 
frequently determined with no or limited binding proteins present, it usually represents an 
unbound concentration [43]. Thus, PK/PD indices also need to be based in free drug 
exposures rather than total concentrations to avoid any bias introduced by considering 
protein binding only in the PD parameter MIC, but not the PK parameters AUC and 
Cmax. Consequently, fT>MIC, fCmax/MIC, and fAUC/MIC based on free drug 
concentrations are now usually applied as appropriate PK/PD indices [40-42, 44]. 
 
 PK/PD indices assessed in M&S studies can be used to assess and compare the 
likelihood of achieving effective target exposure for different antibiotics and thus 
prioritize compounds for the treatment of specific infections.  Noreddin et al. used this 
approach by applying simulation studies to determine the probability of target attainment 
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in serum and epithelial lining fluid (ELF) defined as a fAUC0–24/MIC90 ratio of 30, with 
bacterial eradication as efficacy endpoint, for standard clinical regimens of azithromycin, 
clarithromycin, and telithromycin against S. pneumonia strains with different 
susceptibility [45].  
 
 Another example for establishing PK/PD indices by M&S is the case of isoniazid 
which displays a multimodal elimination pattern in the population based on single 
nucleotide polymorphisms (SNPs) in the gene encoding for N-acetyl transferase-2 
(NAT2).  Since the allelic frequency of these genetic variants differs among different 
ethnic groups, these groups differ in the number of “slow” and “fast” acetylators based on 
NAT2 phenotype. Thus, standard recommended doses would obviously result in different 
bactericidal activities among different populations. In vitro models showed that AUC0-
24/MIC is associated with both microbial death and emergence of resistance for 
isoniazid. Based on this approach, M&S was used to predict the bactericidal effects of 
different doses of drug in various ethnic populations, accounting for the multimodal 
elimination of isoniazid. The model allowed to predict the dose with highest early 
bactericidal activity (EBA) and this dose was used in subsequent clinical studies [46]. 
 
 Based on susceptibility breakpoints microorganisms are classified as susceptible, 
intermediate and resistant based on predefined. The identification of susceptibility 
breakpoints is being performed using standard tests implemented by the Clinical 
Laboratory Standards Institute (CLSI) by examining MIC distributions across different 
strains of a bacterial species. MIC values are measured using Mueller-Hinton broth, as 
recommended by CLSI guidelines [42, 47]. While these test methodologies achieve a 
precise estimate of breakpoints in vitro, the major challenge lies in the ability for clinical 
translation. Since target site exposure and microbial susceptibility will vary among 
different individuals with different infection sites and different pathogen populations, 
susceptibility breakpoints are inherently variable in a clinical population [40]. Thus, in 
vitro derived breakpoints have to be interpreted as point estimates in a breakpoint 
distribution with a confidence interval that presents itself in the clinic [48]. M&S 
approaches using clinical data may contribute to derive and increase the exactness or 
confidence in the derived breakpoints. 
 
 Multiple studies have indicated inconsistencies between the probability of PD 
target attainment (PTA) and susceptibility as per CLSI defined breakpoints. DeRyke et al. 
demonstrated that CLSI susceptibility breakpoints (%SCLSI) overestimated probability 
for achieving bactericidal exposure for antibiotics such as ciprofloxacin, levofloxacin and 
piperacillin-tazobactam against gram negative bacteria such as P.aeruginosa, A. 
baumannii, E. coli and Klebsiella spp. [48]. To overcome this limitation, the authors used 
Monte-Carlo simulations based on published PK data and their between-subject 
variability to define PD derived breakpoints (%SPD). This %SPD accounts for between-
subject variability in human pharmacokinetics as well as exposure differences resulting 
from different dosing regimens. In this approach, %SPD was defined as the highest MIC 
at which at least 90% of the population achieve the targeted bactericidal exposure, and 
bactericidal exposure was defined as fT>MIC (time of free concentration above MIC) of 
40% for carbapenems, 50% for cephalosporins and the piperacillin component of the 
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piperacillin-tazobactam combination, and 125 for the AUC/MIC ratio of 
fluoroquinolones. The analysis indicated that although there was a general lack of 
agreement between PTA and %SPD or %SCLSI, only %SCLSI overestimated the ability 
of the investigated dosing regimens to achieve bactericidal exposures. In contrast, %SPD 
often underestimated PTA, a deviation clinically far less concerning than overestimation. 
The underestimation of PTA using %SPD leads to an overestimation of dose in a 
particular subject (which is preferable), but the general overestimation of doses for a 
population can lead to an increase in bacterial resistance.  Based on the performed 
simulations, the authors suggest pathogen and dosing regimen specific breakpoints as a 
more appropriate way to classify bacteria as susceptible [48].  
 
 
Development of Optimal Dosing Regimens 
 
 One of the top priorities in antibiotic pharmacotherapy is to optimize the duration 
of therapy with proper dosing regimens that are effective and safe, and minimize the 
occurrence of bacterial resistance. However, these goals are often requiring opposing 
measures and can often not be achieved simultaneously. The concept of clinical utility 
can help in optimizing these goals. Clinical utility allows to quantify and optimize “trade-
offs” between multiple factors such as efficacy, safety, microbiology, and usage of drugs 
[49]. Pharmacometrics allows the integration of clinical utility with M&S, where “trade-
offs” can be derived and explored mathematically.  
 
 The clinical efficacy (i.e. bacterial eradication) of drugs such as garenoxacin, 
telithromycin and doripenem is more than 90%. With such high efficacy it is challenging 
to design dosing regimens on the basis of efficacy and safety at varying doses. Population 
based pharmacokinetic M&S using Monte Carlo simulations helped in deciding on a 
dosage regimen by taking into account the between-subject variability in PK parameters 
and varying MIC distributions by various clinical isolates. This approach helped in 
determining the optimal dose for garenoxacin (400mg) on the basis of: 
 
1. Selecting AUC0-24/MIC as an appropriate PK/PD index derived from in vivo 
efficacy data 
 
2. Performing Monte Carlo Simulations using population PK parameters, MIC 
distributions and mutant prevention concentration (MPC) 
 
3. Determining a recommended dose based on probability of target attainment 
 
4. Validation of the recommended dose based on PK/PD data acquired from phase 
III studies for respiratory tract infection [21]. 
 
 Design of dosing regimens is especially challenging for patients who are critically 
ill with severe bacterial infections, and who have renal failure and are on continuous 
venovenous hemodiafiltration (CVVHDF).  In the event of renal failure, dosing regimen 
needs of individual patients can be adjusted by assessing the impact of kidney 
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dysfunction on the disposition of drugs [50]. For example the PK and PD properties of 
biapenem change when a patient is on CVVHDF. Ikawa et al. performed PK M&S to 
determine PD exposure of T>MIC4μg/mL and suggested that for T>MIC4μg/mL for 30% of 
the dosing interval biapenem dosage should be 300mg BID, 600mg BID, or 600mg BID 
for dialysate flow rates of 1.4L/h, 2.8L/h, or 5.6L/h, respectively [14]. As the dialysate 
flow rate increased, T>MIC4μg/mL decreased. The 600mg BID dose was the optimum to 
reach T>MIC4μg/mL of 30% for both dialysate flow rates of 2.8L/h and 5.6L/h. These 
simulations illustrate that low doses or increased dosing intervals should not be 
recommended for patients who are on CVVHDF or renal replacement technique. 
 
 Since critically ill patients often have altered drug distribution and elimination, 
they may experience inadequate dosing with antibiotics and may thus be at a much higher 
risk of infections with antibiotic resistant organisms [51]. For doripenem, a carbapenem, 
T>MIC for 35% of the dosing interval has been the recommendation in patients with 
normal kidney function. Since doripenem is primarily excreted in unchanged form into 
the urine, PK-based Monte Carlo simulations were performed to develop dosing 
recommendations for patients with renal impairment. For mild-stage 2 chronic kidney 
disease (CKD) patients with a creatinine clearance (CLCr) >60mL/min, 500mg should be 
infused over 1h every 8h for bacteria with MIC ≤1μg/mL; however, in the more severe 
stage 3 CKD patients with CLCr ~30-50mL/min, an infusion of 250mg of doripenem over 
1h every 8h for bacteria with MIC ≤2μg/mL is recommended. For patients with severe 
renal impairment with a CLCr of 10-29mL/min, 250mg was recommended to be infused 
over longer durations, 4h instead of 1h, every 12h for MIC ≤2μg/mL. This is consistent 
with the time-dependent (T>MIC) killing pattern of carbapenems. Dosing strategies like 
this can only be achieved from PK/PD M&S where the creatinine clearance builds the 
parameter framework for achieving set exposure levels, as PK studies in critically ill 
patients would be extremely difficult to perform [52].  
 
 In order to be efficacious, an antibiotic needs to reach the site of infection in 
therapeutically effective concentrations. In patients with severe lung infections, the 
concentration of antibiotics in ELF is an essential measure to decide on an optimal 
dosage regimen [25]. It has been reported recently that methicillin-resistant S. aureus 
(MRSA) is the likely culprit in causing more than 25% of all ventilator-associated 
pneumonias in intensive care unit patients [53]. A population PK model with Monte 
Carlo simulations was employed to determine the range of ELF exposure relative to that 
in plasma. It was determined that vancomycin penetrates ELF at approximately 50% of 
plasma concentrations [35]. Under the assumption that the PK/PD in ELF is similar to the 
AUC/MIC of ≥400 used in plasma, the M&S exercise showed that target attainment is 
expected to be suboptimal for MRSA with MICs in excess of 1 mg/L under current 
dosing regimens. A similar approach was used for PD profiling of cefditoren and 
telavancin against penicillin-susceptible and penicillin-intermediate S. pneumonia [15] 
and methicillin-resistant S. aureus, respectively [34].  
 
 The MIC value for an antibiotic varies depending on which organism it acts upon. 
Carbapenems require higher MIC to be effective against P. aeruginosa as compared to 
other bacteria. The antibacterial efficacy of four commonly used dosage regimen for 
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doripenem was determined using an integrated PK/PD M&S approach based on in vitro 
time-kill data and human PK data. The simulations indicated time-dependent 
antimicrobial activity of doripenem, in which the 250mg TID regimen had a higher 
bactericidal effect than did 500mg BID [54]. 
 
 While dosage regimens for most antibiotics can be derived by PK/PD-based M&S 
as outlined in the presented examples, the therapeutic concentration obtained from those 
recommendations may be insufficient to safeguard optimum clinical efficacy and 
bacterial clearance from the site of infection, especially if they are based on studies in 
healthy individuals rather than patients. Hence, it is of utmost importance to take into 
account the disposition (PK) and target site accessibility of antibiotics in diseased 
individuals having abnormal physiological conditions such as renal dysfunction. Along 
these lines, it is often preferred to use in these PK/PD M&S evaluations drug resistant 
bacteria that constitute a worst case scenario. An example for such an approach is the 
dose optimization of norvancomycin against methicillin-resistant rather than non-resistant 
Staphylococcus isolates for patients with different physiological and pathological 
conditions in the Chinese population. The optimized norvancomycin dosing 
recommendations were 800-1000mg BID for patients with normal renal function, 800mg 
QD or BID for patients with mild renal dysfunction (CLCr >50 to ≤ 85mL/min), 800mg 
QD to 2.5days for patients with modest renal dysfunction (CLCr >10 to ≤ 50mL/min), and 
600mg over 5-11days or 800mg over 6-13days for patients with severe renal dysfunction 
(CLCr >5 to ≤ 10mL/min) [28].  
 
 
Optimization of Clinical Studies and Clinical Applications 
 
 Over the last decade, it has become obvious in many examples that fine tuning of 
phase II/III clinical trials as well as post-marketing studies a priori is essential to reduce 
cost and optimize study performance and outcomes. PK/PD based M&S has played a 
major role in this process by integrating observations and data obtained from preclinical 
studies in animals and phase I studies in healthy volunteers as well as phase IIa studies in 
patients. The factors taken into consideration for mathematical modeling are often: 
 
1. MIC distribution patterns in clinical isolates 
 
2. The range of individual PK parameters in the target patient population 
  
3. Identified PD targets from efficacy studies in animals  
 
4. The degree of protein binding.  
 
 The combination of microbiological, preclinical and clinical PK and PD data in 
mathematical models is essential in designing target antibiotic exposures. M&S with such 
data is not only beneficial for single drug therapy but also for the evaluation of multiple 
concurrently used antibiotics and their potential additive or synergistic effects [41].  
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 There is a sustained need for monitoring the PK/PD of antibiotics even after their 
approval and marketing. Rifampin is widely used for treatment of tuberculosis since 
several decades, but there is only limited data on rifampin concentrations in the lungs. 
Using an M&S based simulation study, Goutelle et al. found that the existing dosage 
regimen (600mg/day) for rifampin is suboptimal in most patients. This could be a 
potential contributing factor for the increasing number of tuberculosis infections with 
multi drug-resistant and extremely drug-resistant strains. The authors suggest considering 
higher doses (1200mg/day) of rifampin for an increase in pulmonary concentrations, 
thereby keeping in mind the toxicity and tolerability of such high doses in patients [33].  
 
 M&S may also be useful in developing strategies to minimize the effect of drug-
drug interactions. Voriconazole and fluconazole are two widely used antifungal drugs 
with similar mechanism of action, but a strong drug-drug interaction when immediately 
switching between the two agents. Fluconazole is the most commonly used antifungal 
agent but unlike voriconazole it does not have anti-aspergillosis coverage sometimes 
necessitating a clinical switch. Fluconazole is a CYP2C19 inhibitor and its presence 
inhibits voriconazole metabolism causing substantial voriconazole-related adverse 
effects. Physiologically based PK modeling was used to determine the time lag required 
between the two therapies to avoid potential toxicity, but also minimize the time period 
without effective antifungal exposure which is essential in the event of serious fungal 
infections. The PK simulations demonstrated that a time lag of at least 24h is required to 
switch from fluconazole to voriconazole in order to avoid relevant interactions [36].  
 
 The use of M&S is not only restricted to optimizing dosing regimen and efficacy 
of treatment, but can also be used for building up clinical treatment guidelines. Goldie et 
al. constructed a population model of HIV infection to answer lifetime cost, life 
expectancy, quality-adjusted life expectancy, and quality-adjusted life years in patients 
receiving highly active antiretroviral therapy (HAART) and Pneumocystis carinii 
pneumonia (PCP) prophylaxis.  The simulation exercises were performed to compare 
different criteria of CD4 cell counts for discontinuing primary PCP prophylaxis in 
patients with CD4 cell count increases receiving HAART and second-line PCP 
prophylaxis (such as dapsone, atovaquone, and aerosolized pentamidine) due to 
intolerance to trimethoprim-sulfamethoxazole. The outcome of the exercise showed that 
treatment is cost-effective when PCP prophylaxis is discontinued with CD4 count 
>300/μL, and that in patients intolerant to trimethoprim-sulfamethoxazole dapsone 
therapy is more cost-effective than atovaquone [55].  
 
 
Future Prospects 
 
 The application of pharmacometric analyses using PK/PD based M&S approaches 
has in the recent decade developed into one of the most essential tools for interpreting 
and integrating large and diverse pools of preclinical and clinical data and translating 
them into an informative knowledgebase [5]. It is expedient not only for industry 
professionals to promote internal decision making at critical drug development steps, but 
is also increasingly utilized by regulatory authorities for compiling and analyzing data for 
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approval and labeling. A recent survey shows that during the last decade, the drug 
approval and labeling decisions of more than 60% of submissions for New Drug 
Applications (NDA) to the US FDA were influenced by pharmacometric analyses. For 
30% of the submissions during this period, FDA reviewers performed independent 
pharmacometric analysis [13]. For example, among anti-infectives, an appropriate dosing 
regimen of micafungin for the treatment of esophageal candidiasis was selected based on 
an exposure-response analysis by FDA personnel. The FDA reviewers utilized the phase 
II and III study data to model the relationship between dose and effectiveness, which led 
them to recommend approval of the 150mg over the 100mg micafungin dose due to 
similar maximum efficacy, but a 15% lower rate of relapse [9].  
 
 Another prime example for use of M&S in regulatory decision making is the 
pharmacometrics-based dose selection of levofloxacin for post exposure treatment of 
inhalational anthrax in children. The available data from two PK studies on 47 adults at 
different doses (500mg/kg and 750mg/kg) and 90 pediatric patients who received a dose 
of 7mg/kg were used to develop an integrated population PK model. The model was then 
utilized to derive dosing recommendations for pediatric patients that match adult 
exposure after a 500mg/kg dose with regard to AUC, and maximum and minimum 
concentration during multiple dosing at steady state. Based solely on this M&S approach, 
a dose regimen of 8mg/kg BID for children <50kg and ≥ 6months of age and 500mg QD 
for children weighing ≥50kg was recommended and included in the labeling information 
[56]. 
 
 The US FDA and the European Medicines Agency (EMA) both acknowledge the 
impact of M&S on regulatory approvals, but assess the investigational plans and 
scientific information differently. FDA seems to prefer to conduct pharmacometric 
reviews including independent data analyses for all the submitted applications 
irrespective of whether the sponsor submitted an analysis or not. In contrast, EMA seems 
to consider a pharmacometric assessment only if it is included in the submission by the 
sponsor. EMA might ask for additional pharmacometric analyses, but these should be 
conducted by the sponsor. European regulatory bodies are especially encouraging and 
emphasizing the use of M&S for drugs in pediatrics and for anti-infectives [57-59]. 
Irrespective of these different philosophies in the review process, the emphasis and 
demand of M&S based pharmacometric analyses in drug approval will likely further 
increase the application of M&S throughout the drug development process [8, 30, 60].  
 
 More recently, physiologically based PK and PK/PD modeling (PBPK) is gaining 
more widespread application, predominantly because of improvements in the associated 
M&S methodologies and the availability of more robust and user-friendly software tools 
[61-63]. It is predicted that the use of PBPK will increase over the next years for 
identifying the effects of intrinsic and extrinsic factors modifying drug efficacy and 
safety in patients. PBPK will play a significant role in predicting and deciphering drug-
drug interactions and will be the basis for M&S in special population such as pediatric 
patients or in critically-ill patients [63].  
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 Evidently, pharmacometric analyses have proven their merits in myriad ways 
during the entire process of drug development. However, there is always room for 
improvements for more accurate and precise estimates resulting in more confident 
predictions. This fine-tuning can likely be accomplished by a more prospective 
integration of M&S approaches in each individual development phase, including goal-
oriented and intelligent sample and data collection that specifically addresses and 
supports pharmacometric analyses. Some of the questions that need to be addressed relate 
to the transfer of knowledge from controlled studies to clinical practice: PK parameter 
estimates are generally derived from healthy subjects. How can we assure that PK/PD 
predictions are accurate in patients with variable physiologic function and variable sites 
and types of infection? How can we account for patients with multiple disease 
conditions? How will their confounding illnesses or polypharmacy affect drug exposure 
for the considered anti-infective? How will variability in the strains of microorganisms 
and their response to the survival stress elicited by the anti-infective such as latency and 
resistance development affect treatment outcome? A more systematic and intensive 
assessment of antibiotic concentrations at the site of action such as ELF over the time 
course of therapy might help to provide some of the needed answers. Techniques such as 
microdialysis have been proven of substantial value in assessing active drug 
concentrations in target tissues not as easily accessible as ELF [64, 65].  
 
 In summary, more complex M&S models will likely be established in the future 
that integrate all therapeutic considerations when treating microbial infections. Using 
precise estimates of PK and PD parameters as well as their distributions in populations of 
patients and microorganisms, including their potential interdependencies, will help in 
facilitating more realistic and thus also even more clinically meaningful predictions for 
the in silico evaluation and development of optimal antibiotic dosing regimens, including 
combination therapies. To combat the growing bacterial resistance, we need to rapidly 
increase the available number of effective antibiotics in our armamentarium by relatively 
fast, safe, smart and inexpensive clinical development programs. We believe that M&S 
based pharmacometric approaches hold great promise in facilitating this process and thus 
may serve as a key technology for the development of future generations of anti-
infectives. 
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CHAPTER 2.    CENTRAL HYPOTHESIS 
 
 
 Among the most deadly infectious microorganisms, tuberculosis is a second 
greatest killer worldwide [66]. According to WHO [67], tuberculosis kills approximately 
1.5 million people annually and it was estimated that 480,000 patients developed multi-
drug resistant TB (MDR-TB) in 2013 alone. The existing drug therapies requires 
treatment spans of  4-24 months and efficacy is hindered severely by poor adherence to 
dosing regiments and drug adverse effects. This alarming situation undoubtedly calls for 
the urgent need for the development of novel and more effective treatment options to 
defeat TB [68, 69]. The primary goal for current anti-tuberculosis drug development 
efforts is to shorten the treatment regimen and circumvent drug-resistance mechanisms. 
 
 Our group has designed a novel semi-synthetic series of spectinomycin analogs, 
or spectinamides. All compounds in this series were initially screened using in vitro 
assays. The results from these preliminary studies aided in refining the chemical structure 
of lead compounds and improved their drug-likeness properties for clinical readiness. The 
lead optimization process comprised in vitro and in vivo pharmacological, 
biopharmaceutical, pharmacokinetic (PK) and pharmacodynamic (PD) profiling of 
candidate compounds [70, 71]. Using a pharmacometric approach, we integrated the PK 
and PD properties of spectinamides to better characterize the interplay and 
interdependencies between drug concentration and drug efficacy in models of disease. 
We hypothesized that a pharmacometrics-directed quantitative approach for integrated 
PK/PD characterization is useful for antibiotic lead characterization and highly predictive 
of in vivo antibacterial efficacy.  
 
 
Specific Aim 1 
 
 In this Aim 1 (Chapter 3), we investigated the biopharmaceutics and 
pharmacokinetic properties of select spectinamide agents to determine lead candidate 
compounds and provide the basis for pharmacometrics-directed PK/PD assessments. An 
important aspect in the efficacy and safety of novel drug candidates is the extent of 
distribution and potential accumulation in tissues. In this context, intracellular uptake into 
macrophages is a prerequisite for antibiotic activity against M. tb residing inside infected 
macrophages. To address these questions, we also evaluated the biodistribution profile of 
a radio-labeled spectinamide and cellular uptake of spectinamides into murine 
macrophages. 
 
 
Specific Aim 2 
 
 In Aim 2, we further evaluated the PK/PD relationships of lead compound, Lee 
1599 using an in vitro PK/PD model system which characterizes a dose-response 
relationship in order to facilitate a rational dose-selection for in vivo efficacy trials 
(Chapter 4). While PD assessments under static conditions such as MIC determinations 
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provided only a point estimate of anti-bacterial activity. A more effective way of 
determining the appropriate dosing regimen with optimum efficacy and with high 
correlation between in vitro and in vivo efficacy is through an integrated PK/PD model 
approach. An in vitro PK/PD model is a convenient tool to predict the efficacy, dosing 
regimen of single or combination drug candidates and PK/PD indices (concentration 
and/or time dependent killing) based on dynamic time-kill curves for supporting in vivo 
studies. To test this hypothesis we determined the time-kill effect of Lee 1599 at various 
dosing regimens against M. bovis BCG as model organism. With this data, we developed 
a PD model to describe Lee 1599 mediated bacterial killing. Based on these in silico 
simulations, we were able to predict the optimal dosing regimen for in vivo efficacy 
studies.  
 
 
Specific Aim 3 
 
 In Aim 3 (Chapter 5), we expanded the pharmacometrics-directed quantitative 
PK/PD assessment of Lee 1599 to combination therapies with rifampicin as model 
compound. Traditionally, qualitative methods such as the checkerboard assay have been 
widely used to evaluate possible pharmacodynamic interaction between two agents. We 
applied a three dimensional surface response assay as quantitative pharmacometric tool 
for characterizing the interaction between Lee 1599 and rifampicin and compared them to 
the checkerboard assay. We validated the results of both assays by expanding our 
previously applied with an in vitro PK/PD model (Chapter 3) to drug combination 
therapy and by a comparison to results of in vivo studies in a mouse model of M. tb 
infection. 
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CHAPTER 3.    PHARMACOKINETICS AND BIODISTRIBUTION OF A 
NOVEL SERIES OF ANTI-TUBERCULOSIS AGENTS: SPECTINAMIDES 
 
 
Introduction 
 
 Tuberculosis (TB) is a global pandemic that has a mortality rate of approximately 
1.5 million people per year. The existing drug therapy requires treatment for a span of 4-
24 months. The flaws of this treatment regimen become very apparent once it is 
administered to patient populations, as it is lengthy and complicated resulting in poor 
patient adherence. As a result, many patients discontinue therapy before complete 
eradication of the disease, which subsequently may lead to the development of drug 
resistant strains such as multi drug resistant (MDR), extremely drug resistant (XDR) and 
totally drug resistant tuberculosis (TR-TB) [67, 68, 72-76]. 
 
 With the help of a structure based design process, novel semisynthetic analogs of 
spectinomycin called spectinamides were recently discovered. Spectinamides inhibit 
protein synthesis by selectively binding to the head domain of the 30S ribosomal subunit 
and blocking its translocation [77]. They have also exhibited overcoming an intrinsic 
resistance mechanism by avoiding the tap efflux pump Rv1258c in M. tb. Rv1258c is an 
efflux pump belonging to the ABC (ATP-binding cassette) transporters and is known to 
play an important role in mediating the efflux of different chemical classes and 
antibiotics [78-80]. While spectinomycin is a substrate for Rv1258c resulting in no 
relevant activity against M. tb, the structural modification in spectinamides renders them 
unsuitable as Rv1258c substrate. Thus, the potency of the spectinamide series is a 
product of high affinity for the mycobacterial ribosome and the avoidance of Rv1258c 
efflux pumps [81].  
 
 The primary goal of this chapter is to gain knowledge of the preclinical 
pharmacokinetics of the select compounds in the spectinamide series. We also 
investigated the biodistribution properties of a spectinamide lead, Lee 1329, using a 
radioisotope technique, as well as uptake into macrophages. Knowledge about the extent 
and pattern of biodistribution are crucial PK characteristics that may determine the 
efficacy and safety profile of drug candidates. 
 
 
Materials and Methods 
 
 
Chemicals and reagents 
 
 All tested spectinamides were synthesized in the laboratory of Dr. Richard.E. Lee 
at St.Jude Children’s Research Hospital, Memphis, TN, including Lee 1329 (3’-dihydro-
3’-deoxy-4(R)-(pyridin-2-yl) acetylamino spectinomycin), Lee 1544 (3’-Dihydro-3’-
deoxy-4(R)-(4-chloropyridin-2-yl) acetylamino spectinomycin), Lee 1599 (3’-Dihydro-
3’-deoxy-3’(R)- (5-chloropyridin-2-yl)acetylamino spectinomycin Trihydrobromide), 3'-
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Dihydro-3'-deoxy-3'(R)- (4-(4-chlorophenyl)pyridin-2-yl))acetylamino spectinomycin 
Trihydrobromide (Lee 1601), 3'-Dihydro-3'-deoxy-3'(R)- (2-(pyridin-2-ylamino)thiazol-
4-yl)acetylamino spectinomycin Terahydrobromide  (Lee 1603), 3'-Dihydro-3'-deoxy-
3'(R)- (4-chloro-5-fluoropyridin-2-yl)acetylamino spectinomycin Trihydrobromide (Lee 
1661), 3'-Dihydro-3'-deoxy-3'(R)- (1-methyl-1H-benzo[d]imidazol-2-yl)acetylamino 
spectinomycin Trihydrobromide (Lee 1663) as shown in Figure 3-1. Acetonitrile, 
methanol, HPLC grade water, formic acid and ammonium formate were purchased from 
Fisher Scientific (Pittsburgh, PA). Drug free rat plasma was purchased from Innovative 
Research (Novi, MI). 
 
 
Protein binding 
 
 The plasma protein binding is determined using equilibrium dialysis with ready to 
use RED device inserts from Thermo Scientific (Rockford, IL) in base plates containing 
plasma and buffer chamber for analysis. High and low concentrations (500ng/mL and 
5μg/mL) of test compounds are prepared in rat plasma. 200μL of the plasma sample was 
added to the central compartment and 350μL of blank isotonic phosphate buffer, pH 7.4 
to the peripheral compartment of dialysis base plate. The base plate is covered with 
sealing tape and incubated at 37oC at approximately 100 rpm on an orbital shaker for 4h 
to achieve equilibrium. The drug concentration is determined using an LC-MS/MS assay. 
The free fraction of the drug is calculated as ratio of the concentrations in the buffer and 
in plasma. The results are expressed in terms of %-bound to plasma proteins. 
 
 
Formulation preparation and administration 
 
 Spectinamides (10mg/kg and 100mg/kg) were formulated in plasmalyte solution 
and sterilized by filtration (0.2 micron syringe filter). The IV doses were administered via 
femoral vein catheter followed by flushing the catheter with locking solution. A group of 
5 rats were dosed for each compound and dose level.  
 
 
Pharmacokinetic studies 
 
 The PK studies are performed on catheterized (jugular vein alone for oral study 
(PO) and jugular vein and femoral vein for intravenous (IV) study) male Sprague-Dawley 
rats weighing approximately 225g (8-10 weeks old). The animals were housed in the 
animal facility with 12h of light/dark cycle with food and water available ad libitum at 
University of Tennessee Health Science Center following protocol number 13-4263A. the 
protocol was approved by the Institutional Animal Care and Use Committee at University 
of Tennessee Health Science Center. Test compounds were administered for IV and PO 
studies at a dose of 10mg/kg and 100mg/kg, respectively. Serial blood samples were  
collected pre-dose and at predetermined intervals until 72h. Plasma was separated 
immediately by centrifugation at 10,000 rpm, 4oC for 10min and stored at -80oC until 
analysis. Plasma and urine samples were analyzed for drug concentrations by 
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Figure 3-1. Chemical structure of lead spectinamides with MIC values.
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LC-MS/MS analysis. Blood samples (250μL) were collected at 0.25, 0.5, 0.75, 1.0, 1.5, 
2.0, 4.0, 6.0, 8.0, 12.0, 24.0, 36.0 and 48.0h after drug administration. Urine samples 
were collected at intervals of 0-6, 6-12, 12-24, 24-36 and 36-48h post-dose and stored at -
20oC until analysis. 
 
 
Pharmacokinetic data analysis 
 
 The concentration-time profiles for both PO and IV administration were analyzed 
by non-compartmental analysis. The IV concentration-time profiles were also analyzed 
by nonlinear regression analysis using a 2-compartment open model with bolus input and 
first order output. The area under curve (AUCinf) from time zero to infinity was 
calculated using the trapezoidal rule by extrapolating to time infinity. Mean residence 
time (MRT), defined as the average amount of time a drug particle remaining in a 
compartment of a system upon IV administration was calculated using  
 
??? ?
???????
??????
 
 
where AUMCinf is the area under the moment curve when the concentration-time curve is 
extrapolated to infinity. The systemic clearance (CL) was calculated using the equation  
 
?? ?
??????
?????????
 
 
where Doseiv and AUCinf,iv are the IV dose and area under the plasma concentration-time 
curve from time 0 to infinity, respectively. An estimate of volume of distribution at 
steady state (Vss) was obtained from IV data using 
 
??? ? ??? ? ?? 
 
Oral bioavailability (F) was calculated using  
 
? ?
??????????? ? ??????
????????? ? ????????
? 
 
where Doseoral, Doseiv, AUCinf, iv, and AUCinf,oral are the oral and IV doses and the 
corresponding areas under the plasma concentration-time curves from time zero to 
infinity, respectively. Urinary excretion parameters were calculated from the cumulative 
dose excreted unchanged in urine and the fraction unbound in plasma (fup). Glomerular 
filtration rate (GFR) was taken from the physiologic parameters published by Davies et al 
[82]. The fraction (fe) of the test compound excreted in urine was calculated as the 
cumulative amount of dose excreted unchanged in urine divided by the dose of the test 
compound administered. Renal clearance (CLr) values were determined from the total 
plasma CL and the fraction excreted in urine using fe*CLtotal. The net processes such as 
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filtration, reabsorption and secretion a drug undergoes in the kidney can be evaluated 
using excretion ratio (Eratio). This was calculated using CLr/(fup*GFR). 
 
 
Macrophage uptake assay 
 
 Uptake of spectinamide compounds (Lee 1329, 1443, 1445, 1544, 1599), SP and 
ST into murine macrophages was studied in the J774A.1 cell line (ATCC, Manassas, 
VA). J774A.1 cells were cultured in T25 flasks in Dulbecco's Modified Eagle's Medium 
(DMEM; Gibco, USA) with 10% Fetal bovine serum (Sigma-Aldrich, USA) and 
maintained at 37oC, 5% CO2. Cells were scraped using teflon cell scraper from the T25 
flasks and the final cell density of 2 to 4×105 cells/mL was adjusted using fresh DMEM. 
The cells were allowed to grow for 48h at 37oC until 60-80% confluent in a 6-well plate 
(each plate representing individual time point and concentration). The media was 
aspirated from the wells and fresh DMEM containing a final test compound concentration 
of 25μg/mL or 100μg/mL was added. The plates were incubated at 37oC, 5% CO2 for 
0.5, 1, 4, 8 and 24h. Additional plates were also incubated for 48, 72 and 96h. The media 
containing test compound was aspirated at every time point and the cells were washed 
with ice-cold Dulbecco's Phosphate-Buffered Saline (DPBS) for three times. The cells 
were suspended in 1mL of water and sonicated for 2min. The cell suspension was 
centrifuged for 5min at 10,000 rpm and the supernatant collected was used to determine 
the drug uptake using LC-MS/MS assay. The drug uptake was expressed in terms of 
μL/mg of protein. The protein content in cells was determined using the Pierce BCA 
assay kit (Thermo Scientific, Pierce Biotechnology, IL, USA). 
 
 
Sample preparation and LC-MS/MS analysis 
 
 The plasma and urine samples were prepared by the protein precipitation method 
by adding 50μL aliquots to 200μL methanol (spiked with the internal standard 3′-
dihydro-3′-deoxy-3′(R)-isopropylacetylamino spectinomycin) followed by vortexing for 
1min, centrifugation at 10,000g for 10min at 4oC. The supernatant was separated via 
chromatography on a Luna 3μM hydrophobic interaction liquid chromatography (HILIC) 
100 × 4.6mm column (Phenomenex, Torrance, CA) using a gradient mobile phase of 
methanol and 10mM ammonium formate, pH 2.75, at a flow rate of 0.4mL/min. 
Detection was performed with an API 3000 triple-quadruple mass spectrometer (ABI-
Sciex, Foster City, CA) with electrospray ionization in multiple reaction monitoring 
mode using the compound-specific mass transfers of m/z 453.3/247.3 for Lee 1329, m/z 
459.2/207.2 for Lee 1443, m/z 471.3/207.1 for Lee 1445, m/z 487.2/128.3 for Lee 1544, 
m/z 487.2/207.1 for Lee 1599 and m/z 418.3/207.1 for Lee 1369.  
 
 A calibration curve (range: 1.95 to 5,000μg/L) was constructed for each test 
compound and validated with spiked samples of rat plasma or urine. The peak area ratios 
of analyte to internal standard were linear over the concentration range tested for all 
compounds, with all correlation coefficients (weighted least-square linear regression 
analyses) >0.997. Accuracy (deviation of the analyzed quality-control samples from 
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nominal values) was within ±3% over the entire range of the calibration curve, and the 
precision (coefficient of variation of repeated measurements of the quality-control 
samples) was <2% for all compounds. 
 
 
Biodistribution 
 
 Radiolabeling of Lee 1329 (3’-Dihydro-3’-deoxy-3’(R)-(pyridin-2yl) acetylamino 
spectinomycin Trihydrobromide) compound was performed by Dr.Richard E. Lee’s 
group at St. Jude Children’s Research Hospital. The biodistribution study was conducted 
in Sprague-Dawley rats (N=7, one control and 6 in the treatment group).  The rats were 
administered 3H-1329 intravenously (IV) via a femoral vein catheter at a dose of 
0.9mg/kg body weight (0.87mCi/kg) every 12h for 4.5days. The control rat received 
normal saline only. Serial blood samples were collected at 0 (pre-dose), 0.25, 2, 8 and 
12h after the 1st dose and at 0 (before 8th dose), 0.25, 0.5, 1, 2, 4, 6, and 12h after the 8th 
dose to evaluate the pharmacokinetics after single and multiple dosing. Plasma was 
separated immediately after sample collection by centrifugation (10,000g for 10min at 
4oC) and stored at -80oC until analysis of radioactivity by scintillation counting. Urine 
and feces specimens were collected at 0h (pre-dose) and every 12h after dosing up to the 
end of the study and stored at -80oC until analysis. The volume of urine and weight of 
feces were noted at every sampling point for the calculation of mass balance. One hour 
after the administration of the 9th dose, the animals were euthanized and all major organs 
such as liver, kidneys, spleen, lung, heart, brain, thigh muscle and blood were collected to 
determine tissue distribution and accumulation. Total blood was collected by cardiac 
puncture. Major organs and tissues were collected and stored at -80oC until analysis. 
Total volume of blood, urine, total weight of the organs, muscle and feces was noted for 
the calculation of mass balance. 
 
 
Sample preparation of biological samples for 3H-1329 
 
 Blood  
 
 0.2mL of blood was added to 1mL of Solvable™ (aqueous based solubilizer, 
PerkinElmer, Waltham, MA) in a glass scintillation vial and incubated at 60oC for 1h. 
0.1mL of 0.1 M EDTA-di-sodium solution was added to reduce foaming due to H2O2. 
0.5mL of 30% H2O2 was added in 0.1mL increments and gently agitated after each 
addition to allow reaction and foaming to subside. H2O2 treatment helps to reduce the 
amount of color present, and thus reduces color quench in the final mixture. The mixture 
was allowed to stand for 30min at room temperature to complete the reaction and was 
incubated in a water bath at 60oC for 1h, venting any slight pressure occasionally. The 
sample was then cooled to room temperature and 15mL of liquid scintillation cocktail 
Ultima Gold™ (Perkin Elmer, Waltham, MA) was added. The samples were light 
adapted for one hour before counting the radioactivity using a scintillation counter. 
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 Serum and urine 
 
 The direct addition method was acquired to determine the amount of radioactivity 
in serum and urine. 1.5mL of ethanol and 15mL of liquid scintillation cocktail Ultima 
Gold™ was added in a glass scintillation vial to 0.1mL of serum or 0.5mL of urine and 
shake well. The samples were light adapted for at least one hour before scintillation 
counting. 
 
 Organs and muscle tissue 
 
 Organs (liver, kidney, spleen, lung, heart and brain) and muscle samples were 
prepared by the solubilization method for the determination of accumulated radioactivity. 
50mg of organs or muscle tissue was weighed into a scintillation vial and 2mL of 
Solvable™ was added and heated on a water bath at 60oC for 1 to 3.5h with occasional 
swirling. After cooling to room temperature, 0.2mL of 30% H2O2 was added slowly with 
swirling between additions, and the mixture was allowed to subside any reaction between 
additions of the H2O2. The mixture was heated again at 60oC for 30min for complete 
decolorization. 10mL of liquid scintillation cocktail Ultima Gold™ was added, and the 
samples were light adapted for at least one hour before scintillation counting. 
 
 Feces 
 
  The amount of radioactivity excreted in feces was determined by sample 
combustion with a sample oxidizer (PerkinElmer Model 307 Sample Oxidizer, Waltham, 
MA) and the recovered 3H was analyzed by scintillation counting. Briefly, feces 
specimens of each animal collected at different time intervals were combined together 
and homogenized with 4 volumes of water. Triplicate samples from each animal of 
approximately 300mg of homogenate were placed in the sample oxidizer and combusted 
in an oxygen rich atmosphere to oxidize the tritium present in the samples to water 
(3H2O). The water was separated into a scintillation vial and mixed with 10mL of 
scintillation cocktail Monophase-S (PerkinElmer, Waltham, MA). The samples were light 
adapted for at least one hour before scintillation counting. 
 
 
Sample analysis of biological samples for 3H-1329 
 
 The blood, serum, urine, organs, muscle and feces samples mixed with liquid 
scintillation cocktail as described above were placed in a Tri-carb 2800 TR liquid 
scintillation analyzer (PerkinElmer, Waltham, MA) to determine the tritium activity (3H). 
The radioactivity was measured in terms of disintegrations per minute (DPM) setting the 
energy window from channel 0 to channel 20. The luminescence from the sample was 
reduced by setting a 10min pre-count delay. Samples were counted in the luminescence 
correction mode. The average counting efficiency for 3H is 65.45%. The counting time 
for each sample was 1min and each sample was analyzed three times. The quench 
indicator tSIE (transformed spectral index of the external standard) was used as an 
indicator of a good spectrum.  
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Results and Discussion 
 
 
Biopharmaceutical properties of spectinamides 
 
 As shown in Table 3-1, the molecular weight of spectinamides ranged from 
between 450 to 600Da and is larger as compared to the spectinomycin with weighs 
around 332.3Da. All of the spectinamides are highly hydrophilic in nature with clogP 
between -3 and 0. 
 
 Plasma protein binding is an essential parameter in determining the drug 
distribution, metabolism and elimination. A drug molecule that is circulating in the 
system exists in two variants, protein bound and unbound (free), assuming that the 
protein binding is reversible. The unbound and the bound form exist in equilibrium. The 
unbound (free) drug is the only pharmacologically active drug as it can permeate the cell 
membranes and exert the pharmacological effect on binding to target structure. Thus, it is 
important to estimate the extent of plasma protein binding [43, 83, 84].  
 
 In general, spectinamides showed low to intermediate plasma protein binding in 
rats. The only exception was Lee 1601 with 75% protein binding which can be attributed 
to its increased molecular weight (563Da) as compared to the other lead compounds in 
this series. The low plasma protein binding suggests that a large fraction of molecules is 
freely available to enter the intracellular space for eliciting their therapeutic effect. 
 
 Lee 1544, Lee 1599, Lee 1601, Lee 1603, Lee 1661 and Lee 1666 are 2-
heteroaryl acetic acid amide analogs of spectinomycin that showed potent in vitro activity 
against M. tb. The pharmacokinetic parameters for all these compounds are shown in 
Table 3-1. Following intravenous administration of 10mg/kg in rats, all molecules 
exhibited bi-exponential concentration time profiles with distinct distribution and 
elimination phase (Figures 3-2 to 3-8) except Lee 1601.  
 
 All the lead candidate compounds in the spectinamide series showed comparable 
alpha half-life of 0.58 to 1.06h, except for Lee 1601 with a very low alpha half-life of 
0.28h. The compounds showed prolonged beta half-life, except Lee 1601. This prolonged 
beta phase did not significantly contribute to the overall systemic exposure (AUC) 
because of 100 to 1000 fold lower plasma concentrations than Cmax. This trend is 
commonly seen in aminoglycosides and other amines and is associated with slow release 
of the trapped molecules from deep tissue compartments. This phenomenon may be 
attributed to lysosomal trapping and/or complexation with membrane phospholipids [85-
89]. 
 
 The compounds showed a steady state volume of distribution in the range of 0.8 
to 1.48L/kg except for Lee 1601 and Lee 1661 with Vd of 0.17 and 0.4L/kg, respectively. 
The AUC ranged from 8.3 to 19.3h.mg/L. The AUC for Lee 1599 was slightly lower than 
other spectinamide compounds. The MRT ranged from 0.2 to 1.84h and the mean 
systemic clearance ranged from 0.5 to 1.22L/h/kg. The percent dose excreted unchanged  
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Table 3-1. Physico-chemical properties and pharmacokinetic parameters for spectinamides after intravenous 
administration at 10mg/kg dose. 
 
Name of the 
compound 
MW 
(Da) cLogP 
PB 
(%) 
Cmax 
mg/L 
t½ 
h 
AUC 
h*mg/L 
CL 
L/h/kg 
Vd 
L/kg 
MRT 
h Fe Eratio % F 
Lee 1544  486.9 -2.51 15.0 12.1 1.06 10.7 0.935 0.868 0.931 0.520 1.70 4.00 
Lee 1599 486.9 -2.51 13.0 9.94 0.58 8.37 1.22 0.820 0.680 0.885 3.02 3.47 
Lee 1601 563.0 -0.697 75.0 15.9 0.297 12.7 0.828 0.167 0.197 0.129 1.08 0.377 
Lee 1603 550.6 -2.30 55.0 16.2 1.05 13.7 0.748 1.41 1.84 0.283 1.82 2.03 
Lee 1661 504.9 -2.34 40.0 23.4 0.732 19.3 0.521 0.358 0.687 0.860 1.91 1.75 
Lee 1666 500.9 -2.01 42.0 15.2 1.04 13.6 0.740 1.48 1.98 0.74 2.33 - 
Spectinomycin 332.3 -2.87 13.0 20.6 1.25 16.8 0.602 0.756 0.757 0.553 1.00 - 
 
Notes: MW: Molecular Weight 
cLogP: Calculate logarithm of partition coefficient 
PB(%): Percentage protein binding 
Cmax: Peak concentration in plasma 
t1/2: Alpha half-life 
Fe: Fraction excreted unchanged in the urine 
Eratio: Excretion ratio 
%F: Percent bioavailability is calculated using the AUC values obtained after oral administration at 100mg/kg 
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Figure 3-2. Measured plasma concentration-time profiles (mean ± SEM) after 
intravenous (10mg/Kg) and oral (100mg/Kg) administration of Lee 1544 in rats. 
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Figure 3-3. Measured plasma concentration-time profiles (mean ± SEM) after 
intravenous (10mg/Kg) and oral (100mg/Kg) administration of Lee 1599 in rats. 
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Figure 3-4. Measured plasma concentration-time profiles (mean ± SEM) after 
intravenous (10mg/Kg) and oral (100mg/Kg) administration of Lee 1601 in rats. 
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Figure 3-5. Measured plasma concentration-time profiles (mean ± SEM) after 
intravenous (10mg/Kg) and oral (100mg/Kg) administration of Lee 1603 in rats. 
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Figure 3-6. Measured plasma concentration-time profiles (mean ± SEM) after 
intravenous (10mg/Kg) and oral (100mg/Kg) administration of Lee 1661 in rats. 
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Figure 3-7. Measured plasma concentration-time profiles (mean ± SEM) after 
intravenous (10mg/Kg) administration of Lee 1666 in rats. 
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Figure 3-8. Measured plasma concentration-time profiles (mean ± SEM) after 
intravenous (10mg/Kg) administration of spectinomycin in rats. 
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in the urine (fe) ranged from 13% to 89%. Except for Lee 1601 and Lee 1603, all the 
compounds had a high fe value 0.5, suggesting that the urinary excretion is the major 
route of elimination for these compounds. The Eratio >1 for all the compounds suggests 
active secretion as the net urinary elimination process. 
 
 Following 100mg/kg oral administration in rats, all compounds showed similar 
bi-exponential concentration-time profiles (Figures 3-2 to 3-6) except for Lee 1601. 
However, all tested spectinamides had poor oral bioavailability (F) ranging from 0.4 to 
4%. Due to higher hydrophilicity, these molecules have limited membrane permeability 
that likely leads to the poor oral bioavailability. One of the strategies to improve oral 
bioavailability is by increasing the lipophilicity and reducing the polar surface area 
without compensating the solubility of these molecules. Alternative route of 
administration such as intrapulmonary route can also be assessed to determine an 
improvement in the bioavailability [90-93].  
 
 
Macrophage uptake assay 
 
 It has been commonly observed that macrophage ingest the M. tb as a defense 
mechanism. After being ingested, M. tb continue to survive and multiply within 
macrophages. Hence, it is important that the antimycobacterial agents reach the 
intracellular region where bacteria thrive within macrophage [94-97]. The macrophage 
uptake of spectinamides was evaluated by incubating the spectinamide agents with 
macrophages and quantifying the intracellular uptake of the agents by macrophages. 
Spectinomycin and streptomycin were used as controls for macrophage uptake. 
Spectinamides are chemically derived from spectinomycin and streptomycin is an 
aminoglycoside and also a second line agent to treat tuberculosis. The concentration of 
drug uptake by macrophages after 24h incubation are shown in Table 3-2 and Figure  
3-9. Lee 1329 and Lee 1599 showed significant penetration into macrophages as 
compared to spectinomycin and streptomycin. As shown in Figure 3-10, Lee 1329 has a 
6-fold and Lee 1599 has 5-fold higher uptake into macrophages as compared to 
streptomycin. 1329 also has 2.2 fold higher uptake than spectinomycin. The results 
indicate that spectinamides have substantial intracellular penetration into macrophages. 
 
 
Biodistribution 
 
 Biodistribution studies with radiolabeled compounds provide a foundation in the 
assessment of drug disposition as they provide understandings into mass balance, tissue 
distribution, drug accumulation, circulatory and excretory metabolites, clearance 
mechanisms and pharmacokinetics. This information is crucial to identify potential 
toxicity and safety concerns of novel drug candidates, but also provides basic information 
on systemic exposure [6]. 
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Table 3-2. Mean concentration of drug uptake into J774A.1 murine macrophage 
cell line at 24h for two different doses. 
 
Compounds 
25μg/mL  100μg/mL 
ng/μg protein SEM  ng/μg protein SEM 
Lee 1329 1.17 0.287  4.04 0.753 
Lee 1443 0.44 0.205  0.624 0.187 
Lee 1445 0.762 0.125  2.71 0.411 
Lee 1544 0.413 0.026  1.37 0.036 
Lee 1599 1.04 0.032  3.31 0.055 
SP 0.599 0.099  1.86 0.503 
ST 0.184 0.017  0.68 0.052 
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Figure 3-9. Mean average concentrations (± SEM) of drug uptake into J774A.1 
murine macrophage cell line at 24h. 
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Figure 3-10. Fold differences in drug uptake in J774A.1 murine macrophage cell 
line. 
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Mass balance 
 
 The scintillation assay results revealed that 86.6% of administered radioactivity 
was recovered in urine, feces, blood, muscle and organs throughout the length of the 
study that included 9 doses of 0.9mg/kg 3H-Lee 1329 administered intravenously every 
12h. It is challenging to achieve 100% recovery in mass balance studies due to several 
practical limitations influenced by methodological, analytical or biological factors and 
the quantitative investigation were not performed on all organs and tissues at the 
termination of the study. These results, as shown in Figure 3-11, are in accordance with 
other mass balance studies [98-100]. The samples were collected post 1h after the 9th 
dose for mass balance determination. Approximately 70% of administered 3H-Lee 1329 
was recovered in urine, 12.6% in feces and only 4% from all major organs, muscle tissue 
and whole blood. The residual amount of 13.4% can likely be found in the animal 
carcasses. Urine samples collected every 12h showed similar amount of radioactivity in 
the range of 119.3 to 138.9μCi as shown in Figure 3-12. These results indicate that there 
is no considerable accumulation of drug in the body during multiple dose administration. 
 
Tissue distribution 
 
 The tissue distribution, penetration and accumulation of 3H-Lee 1329 and its 
labeled metabolite was determined by analyzing the distribution of radioactivity to major 
organs and muscles post 1h after administering the 9th dose. The observed data for 
relative and absolute radioactivity for each major organ and tissue are presented in Table 
3-3. The degree of tissue penetration was identified by measuring the fold differences in 
amount of radioactivity per mg of tissue as compared to whole blood Figure 3-13. The 
amount of radioactivity in lungs and spleen was 2.79 and 3.06 fold higher as compared to 
whole blood. This infers that 3H-Lee 1329 possesses good tissue penetration into major 
organs which are the primary site of infections by M. tb. Moreover, the amount of 
radioactivity was less than one fold in other organs such as heart and brain. 
 
Pharmacokinetic profile of radioactivity in serum 
 
 The concentration-time profiles for 3H-Lee 1329 after administration of 1st dose 
and 8th dose are compared in Figure 3-14. The profiles are comparable for both the 
doses for the first two hours with identical Cmax values. However, the concentrations of 
radioactivity was 50% greater after the 8th dose as compared to the 1st dose. This 
differences in concentrations at later time points indicates the possibility of metabolite 
formation circulating with longer half-life than the parent drug. 
 
 Conversely, the systemic exposure (AUC0-τ) of radioactivity after the 1st dose and 
8th dose were found to be very similar because of two reasons (i) The concentrations of 
3H-Lee 1329 2h post dose was very low compared to the Cmax and (ii) these 
concentrations added only 21% of the total exposure (AUC0-τ) (Table 3-4). A comparison 
of the systemic exposure characterized by Cmax and AUC0-τ following the 1st dose and 
8th dose indicated an accumulation ratio R of 1.1, providing further evidence for the 
absence of any substantial drug accumulation. R is a parameter used to quantify the  
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Figure 3-11. Mass balance and percentage distribution of Lee 1329-T at 1h post 9th 
dose of 0.9mg/kg. 
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Figure 3-12. Amount of radioactivity (mean ± SD) excreted in urine after each 
dosing interval (0.9mg/kg 3H-1329, BID for 4.5days). 
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Table 3-3. Tissue distribution and recovery of radioactivity (mean(%CV)) 
following IV administration of 3H-1329 at 0.9mg/kg BID for 4.5days in rats. 
 
Sample/Organ 
Relative amount 
of radioactivity 
[μCi/g tissue] 
Total amount 
of radioactivity  
[μCi] 
% of 
radioactivity 
recovered 
ADMINISTRATION    
Total amount 
administered  
 1432 (3.44)  
RECOVERY    
Blood  0.24 (12.2) 3.47  0.242 (26.8) 
Liver 1.19 (13.7) 11.4  0.796 (5.99) 
Kidney 7.92 (8.98) 16.4 1.15 (10.9) 
Lung 0.64 (9.35) 0.805  0.056 (12.1) 
Spleen 0.69 (11.5) 0.658  0.046 (13.8) 
Heart 0.22 (9.32) 0.219  0.015 (24.9) 
Brain 0.10 (18.1) 0.160  0.011 (39.6) 
Muscle 0.23 (21.8) 24.7  1.72 (34.9) 
Urine  17.90 (21.2)  1003  70.0 (2.99) 
Feces  5.91 (39.6) 181  12.6 (29.8) 
Total amount 
recovered  1242  86.6 (5.09) 
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Figure 3-13. Fold difference (mean ± SD) in tissue distribution of radioactivity 
compared to amount in whole blood (after normalizing the distributions to μCi/mL 
or μCi/mg of blood or tissue). 
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Figure 3-14. Comparison of single and multiple dose pharmacokinetics showing 
average (±SD) serum concentration-time profiles of radioactivity after the 1st dose 
and 8th dose during multiple dosing with 0.9mg/kg 3H-1329 given intravenously 
every 12h. 
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Table 3-4. Serum pharmacokinetic parameters after the 1st and 8th intravenous 
dose of 0.9mg/kg 3H-1329 (values are expressed as mean (%CV)). 
 
Parameter Dosing interval 1st 8th 
tmax (h) 0.25 0.25 
Cmax [mCi/L] 3.39 (7.4) 3.55 (28.9) 
AUC0-? [mCi*h/L] 5.08 (6.8) 5.17 (20.5) 
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extent to which a compound will accumulate during multiple dosing relative to the first 
dose and is calculated as ratio between AUC or Cmax during one dosing interval during 
multiple dosing compared to the first dosing interval. An R value of 1 indicates absence 
of any drug accumulation [101] 
 
 These results confirm that there is no substantial accumulation of 3H- Lee 1329 or 
its metabolites. The recovery of 70% radioactivity in urine and 35-fold higher 
concentration in kidneys compared to blood suggests that renal excretion is the major 
route of elimination (or kidney is the major eliminating organ) for Lee 1329 and its 
metabolites.  
 
 
Conclusion 
 
 Select molecules from the spectinamide series were identified and characterized 
via screening prototype involving various in vitro and in vivo assays. Spectinamides 
demonstrated low to intermediate protein binding, shorter in vivo half-life at clinically 
relevant concentrations and very low oral bioavailability. The compounds in the series 
also expressed higher cellular uptake into macrophages as compared to streptomycin and 
spectinomycin.  
 
 The biodistribution and mass balance study emphasized the favorable 
pharmacokinetic properties of spectinamides as anti-TB agents; augmenting that 
spectinamide Lee 1329 has excellent penetration into target tissues, did not accumulate in 
tissue during multiple dosing, and forms low levels of circulating metabolites that are 
excreted into urine and feces.  
 
 The pharmacokinetic parameters and tissue distribution data obtained in this 
chapter provide the basis for the pharmacometrics-directed integrated PK/PD 
characterizations in Chapters 4 and 5. 
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CHAPTER 4.    A PHARMACOMETRICS-BASED APPROACH USING IN 
VITRO PK/PD MODELING TO DEVELOP DOSING REGIMENS FOR IN VIVO 
STUDIES FOR A NOVEL SPECTINAMIDE ANTI-TUBERCULOSIS AGENT 
 
 
Introduction 
 
 The increasing emergence of resistant mycobacterial strains in recent years and 
the complications arising from treatment regimens are a strong reminder of the urgent 
need for the development of new and more effective treatment options for tuberculosis 
patients worldwide [67, 68, 72, 73]. Spectinamides, a novel class of spectinomycin 
analogs, were designed to combate the increasing TB pandemic [81]. Spectinamides have 
shown potent activity against mycobacteria in vitro and in vivo. Based on in vitro 
screening assays and pharmacokinetic studies in rodents, Lee 1599 emerged as one of the 
lead candidate molecules from the class of synthesized compounds. Lee 1599 has a 
minimum inhibitory concentration (MIC) of 1.6μg/mL, and a favorable pharmacokinetic 
profile with low (12.5%) protein binding, high microsomal metabolic stability, and renal 
excretion as the primary elimination pathway. Although the half-life at effective 
concentrations in rats was with 0.58h is relatively low, this property is counterbalanced 
by a long post-antibiotic effect [81, 102, 103] that last approximately 133h when 
mycobacteria were exposed to Lee 1599 at 10X the MIC. 
 
 The preliminary screening assays for new anti-infectives routinely include MIC 
testing as one of the major pharmacodynamic measures of potency. Although the MIC 
parameter is very informative at the early discovery phase, the limitations of this testing 
method become evident as the in vitro knowledge about MIC can often not correlate very 
well with in vivo efficacy in clinical settings. MIC is just a point estimate of 
pharmacodynamic effect and does not describe the nature of bacterial killing over time 
[39, 104, 105]. Thus, it is essential to have a more dynamic approach that has the ability 
to translate the in vitro bacterial killing effect to in vivo conditions. Various in vitro 
PK/PD modeling approaches have been utilized in recent years to capture the interaction 
of fluctuating drug concentrations with bacterial killing over time. The benefits and 
pitfalls of each method have been described elsewhere [10]. To obtain initial assessments 
on PK/PD drivers of efficacy for new leads in drug discovery programs, a spinner-flask 
based in vitro PK/PD model is a simple tool to generate time-kill curves for mycobacteria 
under exposure to antibiotics. The fluctuating concentration-time profiles of the free, 
pharmacologically active antibiotic as experienced during multiple dosing in vivo are 
simulated in this approach using previously determined in vivo pharmacokinetic 
parameters of the compound 
 
 In this article, we describe the dynamics of bacterial killing by Lee 1599 using an 
in vitro PK/PD model. The Lee 1599 facilitated bacterial killing was characterized at 
multiple dosing regimens by means of M. bovis BCG as model organism. An integrated 
PK/PD model was generated based on the generated bacterial time-kill curves and the 
simulated pharmacokinetic profiles of Lee 1599. Numerical simulations were 
subsequently performed to predict the anti-mycobacterial activity of Lee 1599 for 
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untested dosing regimens. This methodology has potential to guide researchers for 
optimizing the dose selection process and study designs for further in vivo efficacy 
testing. 
 
 
Materials and Methods 
 
 
Culture, media and antibiotics 
 
 M. bovis BCG was grown in Middlebrook 7H9 broth (Becton 
Dickinson, Sparks, MD). The cultures were stored at -80°C in Middlebrook 7H9 broth. 
For each experiment, cultures were thawed and incubated at 37°C in Middlebrook 7H9 
broth until the bacteria reaches logarithmic phase (OD600 0.4-0.7). Lee 1599 (3’-Dihydro-
3’-deoxy-3’(R)- (5-chloropyridin-2-yl)acetylamino spectinomycin Trihydrobromide) was 
synthesized and provided by our collaborators at St.Jude Children’s Research Hospital. A 
solution of Lee 1599 was freshly prepared in sterile water before the start of each 
experiment. 
 
 
In vitro PK/PD model 
 
 As previously reported [39], the in vitro PK/PD model system consisted of a two-
armed, water jacketed flask (1965 series spinner flask, Bellco Glass, Vineland, NJ) as 
depicted in Figure 4-1 [71]. A filter unit attached to a hollow steel tube is introduced into 
the system. The filter unit contains a prefilter (5μm, Millipore, Billerica, MA) and filter 
membrane (0.22μm, Millipore, Billerica, MA) to prevent leakage of bacteria during the 
dilution process. The other end of the tube is connected to plastic tubing (PharMed 
tubing, Cole-Parmer, Vernon Hills, IL) from which the media is withdrawn continously 
at a defined flow rate using a peristaltic pump (Masterflex L/S, Cole-Parmer, Vernon 
Hills, IL). The flask is placed on a magnetic stirrer for homogeneity of the culture and 
preventing membrane blockage. The temperature of the system is maintained at 37oC 
with the help of thermostatic water bath attached to the water-jacketed flask. One arm of 
the flask in connected by plastic tubing to the fresh sterile media reservoir and the other 
arm is used for dosing and repeated sampling. The solution of Lee 1599 is added through 
the sidearm. The concentration of Lee 1599 in flask decreases exponentially as per the 
equation: 
 
? ? ?? ? ????? 
 
 C0 is the initial concentration of Lee 1599 in the flask following administration, C 
is the concentration of Lee 1599 at any given time t, k is the elimination rate constant. 
 
? ?
??
??
?
?
??
?
?????
????
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Figure 4-1. A representation of working unit of an in vitro PK/PD model. 
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where CL is the clearance of 1599, Vd is the Volume of distribution of 1599, F is the 
flow rate of the media depicting Clearance, Vm is the volume of media in the flask, and 
t1/2 is the half-life of 1599. All the above mentioned PK parameters were from obtained 
by performing PK study in rats. The in vitro set up is assembled in a biosafety cabinet in 
a sterile environment. The flask and the tubes are cleaned and sterilized by autoclaving 
before starting every experiment.  
 
 
Time kill curves for Lee 1599 
 
 M. bovis BCG was used as a test organism for evaluating the effect of Lee 1599 in 
vitro model. The organism was grown to early logarithmic phase (O.D600. 0.4-0.7) in 
Middlebrook 7H9 medium. This actively growing bacteria was used as an inoculum for 
the in vitro model making the final density in the culture as 106 CFU/mL.  
 
 In separate experiments, different dose levels and dosing intervals of Lee 1599 
were tested. The dosing regimens tested were 1mg QD, 5mg QD and BID, 10mg QD and 
BID, 20mg QD, 25mg QD and BID, 50mg QD and BID and 100mg QD. Samples with an 
approximate volume of 200μL were collected from the flask every 12h. The samples 
were centrifuged at 10,000 rpm for 10min at 37oC. The pellets were collected and re-
suspended in an antibiotic-free medium. This step ensured that there was no drug carry 
over effect. The samples were serially diluted and the dilutions were plated on 7H11 agar 
plates in duplicates. The agar plates were incubated for 21days at 37oC. The effect of Lee 
1599 was characterized by measuring the reduction in the number of viable bacteria, in 
terms of CFU/mL. There was a control arm included in the study to determine the 
bacterial growth in absence of drug.  
 
 
PK/PD model building 
 
 The chemostat flask in the in vitro system resembled the central compartment and 
total amount of drug administered in the central compartment. The concentration-time 
profiles of the drug in the in vitro PK/PD model system were described with a simple 
one-compartment model with first-order elimination: 
 
? ? ?? ? ????? 
 
 where C is the concentration of Lee 1599 at any given time t, C0 is the 
concentration of Lee 1599 at time 0h, k is the elimination rate constant.  
The rate of change in the number of bacteria in the presence of drug was modeled using 
the full PK/PD model as shown in Figure 4-2. The bacterial submodel and the PK model 
were combined and the parameters are combined to characterize the effect of antibiotic 
Lee 1599 on M. bovis BCG [105, 106] as shown in the equation below. 
 
??
??
? ??? ? ?? ?
?
????
? ? ?? ? ????? ? ?
???? ? ?
???? ? ?
?? ? ? 
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Figure 4-2. Schematic representation of PK/PD model to describe the rate of 
change in the number of bacteria in the in vitro PK/PD model system. 
 
Notes: C: Concentration of drug in central compartment 
F: Bioavailability 
ke: Elimination rate constant 
ko: Growth rate constant 
Ns: Total number of susceptible bacteria in the system 
α: Delay rate constant 
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 The parameters in the equation are as follows: N is the number of viable bacteria 
in the system, k0 is the bacterial growth rate constant, Nmax is the maximum number of 
bacteria grown in the system in the absence of antibiotic, α is the delay rate constant for 
growth, Imax is the maximum kill rate of the bacteria, C is the concentration of the drug 
in the system at a given time point, IC50 is the inhibitory concentration at half maximal 
kill rate. The logistic growth function added to the equation implies that the entry into the 
stationary phase is attributed to self-limiting growth of bacteria. The delay rate constant 
in incorporated to take into account the time taken by the drug to reach the site of action 
in bacteria. 
 
 The time kill curves were analyzed using non-linear mixed effects modeling 
(NONMEM v.7.2, ICON plc). The pharmacokinetic parameters were fixed in the 
described PK/PD model to the following values: V=55mL, volume of media in the 
system; half-life t1/2 = 0.58h. The first order conditional estimate method within 
NONMEM was used to analyze the experimental time-kill curves. The between 
experimental variability was modeled as proportional error. The model was evaluated 
using various goodness of fit plots.  
 
 The appropriate PK/PD index associated with the bacterial kill by Lee 1599 was 
determined by calculating the individual indices and subsequently fitting an inhibitory 
Emax model to the colony count at a specific time point versus PKPD index data using 
nonlinear regression: 
 
? ? ?? ? ?
???? ? ?????????
???? ? ?????????
? 
 
where, E is the observed M. bovis BCG counts in Log CFU/mL, E0 is the bacterial count 
in the control experiment, Emax is the maximum anti-bacterial effect in Log CFU/mL and 
EC50 is the value of PK/PD index that produces half-maximal antibacterial effect. 
PKPDindex is one of three empirical PK/PD indices frequently used for antibiotics 
pharmacotherapy such as AUC0-24/MIC, Cmax/MIC or T>MIC. The most appropriate 
PK/PD index that best described the bacterial killing was selected based on visual 
inspection and goodness of fit criteria.  
 
 
Numerical simulations 
 
 Numerical simulations were performed using the developed PK/PD model and the 
parameter estimates derived from the time kill experiments to predict the effect of 
different untested doses and dosing regimens in a murine in vivo infection model of 
mycobacteria. The PK parameters of Lee 1599 in mouse were obtained from a mouse 
bridging studies as published elsewhere[81]. Dosing regimens ranging from 1mg/kg to 
200mg/kg with QD, BID and TID dosing were simulated using the in vivo PK parameters 
and PK/PD estimates obtained from experimental time kill curves. 1000 datasets were 
simulated for each dose/dosing regimen using NONMEM 7.2 
 
 55 
Results 
 
 
Time kill curves for Lee 1599 
 
 The bacillary load in tuberculosis patients varies from 6-9 log CFU/mL in cavity 
walls [107]. Thus, the experiment was initiated with a bacterial burden of approximately 
6 log CFU/mL and 7 log CFU/mL. The time kill experiments were carried out for Lee 
1599 against M. bovis BCG with various dose and dosing regimens as shown in Figure 
4-3 (N0: 6-7 log CFU/mL) and Figure 4-4 (N0: 7-8 log CFU/mL). The samples were 
collected every 12h up to 96h (Day 4) for all the studies. All the studies were performed 
in duplicate (N=2). LC-MS analysis has demonstrated that Lee 1599 is stable in 7H9 
media for up to 144h. The untreated control group showed a 2-log increase in bacterial 
growth through the length of the study. The lowest treatment dose of 1mg/kg QD dosing 
did not show any change in bacterial counts, indicating similar doubling time and death 
rate. At 5mg/kg QD and 10mg/kg QD, Lee 1599 showed a bactericidal effect and a 
decrease in bacterial count was observed. However, Lee 1599 did not show a significant 
difference (p>0.05) in bacterial counts at a very high dose of 100mg/kg QD compared to 
50mg/kg QD (p=0.0729 at 48h and p=0.278 at 72h). The antibiotic effect improved 
substantially with BID and TID dosing as compared to QD dosing using the same daily 
dose. An increase in bacterial killing was observed with 5mg/kg BID (10mg/kg/day) and 
3.33mg/kg TID (10mg/kg/day) as compared to 10mg/kg QD dosing. Similarly, 50mg/kg 
BID (100mg/kg/day) dosing was more effective than 100mg/kg QD. 
 
 The time kill curves for M. bovis BCG were described using a semi-mechanistic 
PK/PD model. The effect of Lee 1599 on bacteria was characterized by incorporating an 
inhibitory sigmoidal Emax model with delay rate constants that reduced the growth rate 
in a concentration-dependent fashion. The growth rate constant was estimated to be 
0.0368h-1 that equals to a doubling time of 18.83h. The doubling time is in accordance 
with the values reported in the literature [108, 109] indicating that the growth rate was 
not affected by the in vitro PK/PD model system. A maximum bacterial kill rate (Imax) 
was calculated as 0.0355h-1, suggesting that it takes nearly 19.5h for the bacterial counts 
to be halved. The concentration of the drug required to produce half-maximum inhibition 
(IC50) was calculated as 0.0437mg/mL. A delay rate constant was introduced in the 
equation to explain the delay in the initiation of the actual killing effect. The delay rate 
constant was estimated to be around 0.0209h-1. The results of this analysis are shown in 
Table 4-1 and the model diagnostics and predictions for various dosage regimens are 
shown in Figures 4-5 and 4-6.  
 
 The PK/PD index for Lee 1599 was determined using a sigmoidal inhibitory 
Emax model. The bacterial kill on Day 2, 3 and 4 (only Day 4 data shown) suggested that 
Lee 1599 follows both AUC/MIC and Cmax/MIC as PK/PD index (Figure 4-7). Besides 
visual inspections, various model diagnostics such as AIC, BIC and -2LL are used to 
estimate the relative quality of statistical models and as a means of model selection. 
These goodness-of-criteria also demonstrated that AUC/MIC and Cmax/MIC are 
appropriate PK/PD indices as compared to T>MIC (Table 4-2). AUC/MIC index  
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Figure 4-3. Timekill effect of Lee 1599 against M. bovis BCG (N0: 6-7 log 
CFU/mL) with observed log CFU/mL plotted against time for different dosing 
regimens. 
 
  
Time (h)
0 24 48 72 96 120
Lo
g 
C
FU
/m
L
0
2
4
6
8
10
100mg QD 
10mg QD 
1mg QD 
3.33mg TID 
50mg QD 
5mg BID 
5mg QD 
Control 
20mg QD 
10mg BID 
 57 
 
 
 
Figure 4-4. Timekill effect of Lee 1599 against M. bovis BCG (N0: 7-8 log 
CFU/mL) with observed log CFU/mL plotted against time for different dosing 
regimens. 
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Table 4-1. In vitro PK/PD parameter estimates for Lee 1599. 
 
Parameter Estimate 
(%RSE) 
Between 
experimental 
variability 
(%RSE) 
Residual error 
(%RSE) 
α (h-1) 0.0209 (49%) 0.754 (38%) 0.00591 (32%) 
Ko (h-1) 0.0368 (40%) 0.124 (106%)  
N (CFU/mL) 6.82 (2%) 0.00304 (85%)  
Nmax (CFU/mL) 8.27 (4%) 0.00483 (57%)  
Imax (h-1) 0.0355 (27%)   
IC50 (mg/mL) 0.0437 (61%)   
 
Notes: RSE: Residual Standard Error 
α: Delay rate constant 
Ko: Growth rate constant 
N: Initial number of bacteria 
Nmax: Maximum number of bacteria 
Imax: Maximum bacterial kill rate 
IC50: Concentration required to produce half-maximal effect 
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Figure 4-5. Panels showing goodness of fit plots for the Lee 1599 PK/PD model fit 
(A.) DV vs PRED (B.) DV vs IPRED (C.) PRED vs CWRES (D.) TIME vs CWRES. 
 
Notes: (A.) Observed effect (DV) vs population prediction (PRED) 
(B.) Observed effect (DV) vs individual prediction (IPRED) 
(C.) Population prediction (PRED) vs conditional weighted residuals (CWRES) 
(D.) Time vs conditional weighted residuals (CWRES) 
CWRES is a model diagnostic for evaluating model misspecification. It is calculated 
based on first order conditional estimate (FOCE). 
 
(A.) (B.) 
(C.) (D.) 
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Figure 4-6. Plots showing measured (DV is observed data), individual predictions 
IPRED (black lines) and population predictions (red lines) for M. bovis BCG 
CFU/mL over time for the Lee 1599 PK/PD model.  
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Figure 4-7. Relationship between PK/PD indices and microbial kill on Day 4 after 
treatment.  
 
Notes: Panels A, B and C shows AUC/MIC, Cmax/MIC and T>MIC, respectively. The 
red dots are observed data points and blue lines are model predicted lines. 
 
A.) B.) 
C.) 
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Table 4-2. Empirical PK/PD indices based on day 4 data. 
 
Parameter AUC/MIC (%CV) Cmax/MIC (%CV) T>MIC (%CV) 
EC50 14.7 (71.03%) 3.63 (79.06%) 1.42 (211.8%) 
Econtrol 10.2 (20.7%) 11.2 (28.4%) 12.2 (65.2%) 
Emax 8.09 (24.09%) 8.97 (32.5%) 9.70 (68.6%) 
AIC 48.3 47.9 56.4 
BIC 50.4 50.09 58.5 
 
Notes: EC50: Effective concentration to achieve 50% of maximal effect 
Econtrol: Initial M. bovis BCG counts in absence of drug (at time 0, pre-treatment) 
Emax: Maximum effect achieved on Day 3 
AIC: Akaike information criterion 
BIC: Bayesian information criterion 
%CV: % Coefficient of Variation 
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suggests that Lee 1599 follow both concentration and time dependent killing as opposed 
to time dependent killing pattern observed commonly with aminoglycosides. The 
potential explanation for the difference in PK/PD index of Lee 1599 and other 
aminoglycosides can be related to the lengthy post-antibiotic effect (PAE) of 133h for 
Lee 1599 at 10X MIC. This can be achieved clinically by administering higher doses 
more frequently so that higher concentration of drug stays above MIC for longer periods 
in spite of clinically relevant shorter half-life for Lee 1599.  
 
 
Numerical simulations 
 
 The pharmacokinetic parameters from a mice bridging study and 
pharmacodynamic parameters from the in vitro time kill experiments were combined in a 
PK/PD model as shown in Figure 4-8. Numerical simulations for time-kill curves were 
performed utilizing parameters from this PK/PD model to predict the effect ascertained 
by Lee 1599 at various untested dosing regimens in mice. The simulated profiles for QD, 
BID and TID dosing regimens are shown in Figure 4-9, 4-10 and 4-11 respectively. The 
simulations also suggest that there is a dose dependent killing indicating an evident dose 
response relationship. The efficacy was higher with increasing doses for all the three 
regimes, however, for TID dosing regimen, there was a ceiling effect observed at very 
high doses of 50mg, 100mg and 200mg TID. Although the total daily doses were the 
same, BID and TID dosing showed better efficacy as compared to QD dosing regimens.  
 
 
Discussion 
 
 The urge to combat tuberculosis is constantly on the rise and numerous research 
groups have discovered new drugs and tested globally. The preliminary screening of 
these drugs during the early discovery program are often based on target inhibition 
studies and MIC testing. The monitoring of the dynamic interplay between the drug and 
bacteria becomes more relevant as the concentration of drug changes over time in vivo as 
opposed to the static time kill studies of MIC testing where the concentration of drug 
remains constant throughout the course of the study. Several research groups have 
performed static time kill studies using bacteria that have very fast doubling time [110]. 
Since, M. tb have a lengthy doubling time, it might be even more misleading to perform a 
time kill study under static conditions. Hence, the need for dynamic in vitro PK/PD 
models are evident. The utility of dynamic models such as the applied in vitro PK/PD 
model is primarily to identify the nature and time course of the anti-bacterial effect 
obtained from the antibiotic in question and to apply these findings to extrapolate the PD 
effect to the in vivo situation.  
 
 The time kill curves for Lee 1599 showed dose-dependent killing with the tested 
dosing regimens. The estimates obtained from semi-mechanistic PK/PD model were used 
for numerical simulations of the kill dynamics of varying dosing regimen in a mouse 
model of tuberculosis infection under the assumption of an absence of the animal’s 
immune response. For this purpose, PK parameter estimates were used from a mouse 
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Figure 4-8. Schematic representation of PK/PD model used for simulations. 
 
Notes: * indicates that the bioavailability of 1 was assumed for modeling and simulation 
purposes. SC is subcutaneous route of administration, C is the central compartment and P 
is the peripheral compartment. The pharmacokinetic parameter estimates were obtained 
from PK studies performed in mice.  
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Figure 4-9. Time kill curves calculated from 1000 numerical simulations for once 
daily dosing regimen of Lee 1599 in mice.  
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Figure 4-10. Time kill curves calculated from 1000 numerical simulations for twice 
daily dosing regimen of Lee 1599 in mice. 
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Figure 4-11. Time kill curves calculated from 1000 numerical simulations for 
thrice daily dosing regimen of Lee 1599 in mice. 
 
  
Time (h)
0 24 48 72 96 120 144 168
Lo
g 
C
FU
/m
L
0
2
4
6
8
100mg TID 
10mg TID 
1mg TID 
200mg TID 
50mg TID 
5mg TID 
Control 
 68 
bridging studies previously performed by our group. The simulations using mouse PK 
parameters suggested that Lee 1599 elicits exposure (concentration and time) dependent 
killing as opposed to only dose dependent killing. For QD dosing regimens, the 
simulations indicate regrowth in the bacterial counts once the drug is cleared from the 
system. This can be possible due to short half-life of the Lee 1599 at clinically relevant 
concentrations. The regrowth could not be captured in vitro model system because of the 
limited number of sampling time points. The compound still causes a significant bacterial 
reduction with QD regimen at higher doses. With BID and TID regimen, a similar effect 
in efficacy is observed for higher doses 50mg, 100mg and 200mg. At such high doses, 
there is a dramatic reduction in bacterial counts reaching sterilization. However, 
prolonged administration at such high doses is not necessary as similar efficacy can be 
achieved at a dose lower than 50mg BID. 
 
 We also performed simulation exercises with the dosing regimens used for the in 
vivo efficacy trials by our collaborator Dr.Lenaert’s and her group at Colorado (5 days a 
week with 2 consecutive drug holidays) in order to visualize the effect of dosing holidays 
with regards to efficacy of Lee 1599 in mice. The simulations are shown for QD and BID 
dosing in Figure 4-12 and 4-13. These simulations are stochastic simulations taking into 
account the drug holidays and prediction intervals. The simulated effect was the bacterial 
log reduction in the central compartment. There is a regrowth of bacteria observed during 
the holiday period. With QD dosing, only 200mg/kg showed a significant effect as 
compared to other dose groups. There was no efficacy observed at doses up to 40mg/kg. 
In BID dose groups, there was a substantial decrease in bacterial counts at doses above 
20mg/kg BID (i.e. 40mg/kg/day). This suggests that higher doses with shorter dosing 
intervals are desirable for accomplishing an optimal antibacterial effect for Lee 1599. The 
simulations of the in vivo efficacy trials also helped us in understanding the relevant 
PK/PD index. It clearly suggests that, both, higher exposure of drug and shorter dosing 
intervals are required to achieve optimal effect. This finding correlates well with the 
identified relevant PK/PD index of AUC/MIC.  
 
 However, the simulations based on the in vitro PK/PD model may not be 
extrapolated precisely and quantitatively to predict the in vivo conditions due to several 
factors. The PK/PD model established from the in vitro PK/PD model provides 
information about direct interaction of drug with bacteria in the absence of the immune 
system. Also, 100% of drug is available at the site of action i.e. the bacteria in the central 
compartment of the in vitro PK/PD model without any barrier for drug distribution such 
as biomembranes. In contrast, in the in vivo situation, the bacteria reside in the lungs and 
localized within the alveolar cellular compartment (and spleen) as well as within 
macrophages and the drug has to permeate into the lung tissues to cause the desired 
effect. The results might be more accurate if we obtain further information such as 
biodistribution in lung tissues and subcellular compartment with respect to plasma. 
 
 In addition, the drug is administered subcutaneously in the in vivo efficacy trials 
in mice and the bioavailability of Lee 1599 is unknown for this route of administration in 
mouse. The model prediction assumes bioavailability of 100% reaching the lung tissues 
for numerical simulations, which may not be the case. Also, different bacterial strains  
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Figure 4-12. Time kill curves calculated from 1000 numerical simulations for once 
daily (5 days a week) dosing regimen of Lee 1599 in mice. 
 
Notes: The shaded region (grey zone) is the 90% confidence interval and the dark lines 
are the mean bacterial counts in log CFU/mL.  
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Figure 4-13. Time kill curves calculated from 1000 numerical simulations for twice 
daily (5 days a week) dosing regimen of Lee 1599 in mice. 
 
Notes: The shaded region (grey zone) is the 90% confidence interval and the dark lines 
are the mean bacterial counts in log CFU/mL.  
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were used for the in vivo studies (M. tb. Erdman) and the in vitro PK/PD model (M. bovis 
BCG) which may affect the model based predictions of in vivo efficacy trials. The 
doubling times and the logarithmic growth phase of bacteria can be effected under in 
vitro and in vivo conditions. Despite these shortcomings, it is beneficial to perform 
studies using an in vitro PK/PD model and execute pharmacometric analyses to gain 
knowledge about the dose fractionation studies and identifying PK/PD indices. These in 
vitro studies helped us in facilitating the decision making process during the transition to 
in vivo studies. It aided us in selecting an appropriate dosing regimen for in vivo trials in 
order to characterize an exposure-response relationship. 
 
 
Conclusions 
 
 We successfully determined the time kill profiles for dosing regimens of Lee 1599 
against M. bovis BCG. The semi-mechanistic PK/PD model was competent to describe 
the effect of Lee 1599 on the growth and survival of bacteria. The simulations suggested 
that higher doses are more effective than very low doses irrespective of the frequency of 
dosing. The optimal effect in in vivo mouse models can likely be achieved with twice-
daily dosing regimens. These findings support the rational of utilizing a PK/PD based in 
vitro model system to characterize the dose response relationship of spectinamides and 
obtain an understanding of the best PK/PD index as driver of efficacy and the effect of 
dose fractionation studies to maximize efficacy for in vivo trials. 
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CHAPTER 5.    APPLICATION OF PHARMACOMETRIC TOOLS FOR 
IDENTIFYING PHARMACODYNAMIC INTERACTIONS IN ANTIBIOTIC 
COMBINATIONS 
 
 
Introduction 
 
 The mechanism of action for spectinamides is similar to that of spectinomycin-
inhibiting protein synthesis by selectively binding to the head domain of the 30S 
ribosomal subunit and blocking its translocation [77]. Although there can be multiple 
redundancies or alternate pathways in response to such inhibition by a single antibiotic, 
most often this results in drug resistance or clinical relapse. For these reasons, 
combination therapies are needed for more durable and effective treatment [111] 
Combination therapy of new and existing anti-TB agents are constantly being evaluated 
to determine the pharmacodynamic interaction between two agents. The selection of 
combination compounds will aid in treating patients with MDR-TB and also shorten the 
duration of treatment [112].  
 
 The primary objective of this research study was to find a combination partner 
agent for lead spectinamide molecule Lee 1599. We selected rifampicin (RIF) as a model 
compound for combination agent as rifampicin has been in use for TB therapy for several 
decades. The elementary justification for combination therapy is expecting an enhanced 
pharmacodynamic effect with two or more agents. The net effect of any 
pharmacodynamic interaction can be synergistic, antagonistic or additive. The screening 
for an efficacious partner agent for a new molecule is a critical step in the early discovery 
phase before performing any extensive in vivo trials. 
 
 To determine the interaction between the two agents, we applied the widely 
accepted checkerboard assay method as a primary screening tool. The checkerboard assay 
can be used for qualitative interpretation only as it does not provide any information on 
the degree of interaction between Lee 1599 and RIF. An alternative approach is to 
quantitatively assess the interaction by utilizing a parametric method known as three 
dimensional surface response assay. The basis for both these methodologies is set on 
different principles [113-115]. Thus, the expected outcome for an interaction between 
two drugs may or may not be similar from these methodologies. It is essential to identify 
an appropriate screening tool for selection of candidate compounds as it helps in 
accelerating the preclinical drug development process. 
 
 Herein, we illustrate the differences in outcomes of the checkerboard assay and 
the response surface assay, which is instrumental in screening the potential combination 
compounds that are urgently required to curb evolving resistant strains. The results of the 
surface response assay were validated using an in vitro PK/PD model for combination 
therapy by generating dynamic time kill curves at different dose levels and dosing 
regimens. Further, we compared these results of the pharmacodynamic interaction 
between Lee 1599 and RIF with in vivo studies in a mouse model of infection to further 
validate our outcomes. 
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Materials and Methods 
 
 
Antimicrobial agents 
 
 The spectinamide Lee 1599 (3’-Dihydro-3’-deoxy-3’(R)- (5-chloropyridin-2-yl) 
acetylamino spectinomycin Trihydrobromide) was synthesized in the laboratory of Dr. 
Richard.E. Lee at St.Jude Children’s Research hospital. Rifampicin (RIF) was purchased 
from Sigma (St. Louis, MO). A stock solution of each agent was prepared and stored at 
4°C. Prior to each susceptibility testing, an aliquot of each agent was diluted to the 
desired concentration with 7H9 media. 
 
 
Microorganisms 
 
 M. bovis BCG was grown in Middlebrook 7H9 broth (Becton Dickinson, Sparks, 
MD). The cultures were stored at -80°C in Middlebrook 7H9 broth. For each experiment, 
cultures were thawed and incubated at 37°C in Middlebrook 7H9 broth until the bacteria 
reaches logarithmic phase (OD600 0.4-0.7). M. tb Erdman (TMC 107, ATCC 35801) was 
used as testing organism for animal studies. 
 
 
Checkerboard assay 
 
 The pharmacodynamic interaction between Lee 1599 and RIF against M. bovis 
BCG was evaluated using the checkerboard assay. The assay was carried out in 96-well 
plate format with varying concentrations of Lee 1599 and RIF serially diluted in 7H9 
media across rows and columns, respectively. The concentrations for Lee 1599 and RIF 
ranged from 0.003 to 6.4μg/mL and 0.00049 to 2μg/mL, respectively, with a final 
volume of 100μL in each well. Additionally, 100μL of M. bovis BCG culture with OD600 
of 0.01 was also added to each well. The plate was incubated for 7 days at 37°C and the 
endpoint assessment was based on visual growth inspection. The fractional inhibitory 
concentration index (FICI) calculated for each concentration in each combination is 
represented by the following equations: 
 
??????????????????????? 
 
?????????? ?
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FICI represents the extent of interaction between two drugs in question and the 
interaction can be defined as synergistic (FICI < 0.5), antagonistic (FICI > 4.0) or 
additive (0.5 < FICI < 4.0). 
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Response surface assay 
 
 Static time-kill studies were performed in a 5x5 array with different concentration 
combinations for Lee 1599 and RIF. Five concentrations of each agent, 0 (Control), 0.05, 
0.5, 1 and 2X MIC, were used. M. bovis BCG was grown to the logarithmic phase (OD600 
0.4-0.7) in Middlebrook 7H9 medium. The logarithmically growing culture was then 
used to initiate the time kill studies (starting OD600 0.15). The final concentration of 
bacterial culture in each tube was approximately 108 CFU/mL.  The culture was treated 
with different antibiotic concentrations for 24h at 37°C on a shaker (200 rpm). Bacterial 
samples were collected from each tube after 24h for quantification. Prior to 
quantification, the samples were centrifuged at 37°C at 10,000 rpm for 10min and the 
supernatant was discarded. This step is required to ensure that there is no antibiotic carry 
over effect. The bacterial pellet was diluted with the same amount of fresh 7H9 media 
and serially diluted with 7H9 media. The dilutions were plated on 7H11 agar plates for 21 
days at 37°C and the colonies were counted manually on each plate post-incubation. The 
anti-bacterial effect was determined as the decrease in number of viable bacteria in terms 
of CFU/mL.  
 
 The antibacterial effect after 24h of treatment with drugs was described using an 
inhibitory Emax model. The parameter estimates describing the killing effect were 
estimated by nonlinear regression analysis using Phoenix WinNonlin 6.3 (Certara, NJ). 
The total bacterial density for the treatment groups was then modeled with the obtained 
parameters using three dimensional surfaces. Null interaction (or additivity) was used to 
model the effect summation for combination treatment as follows:  
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where E0 is the growth at 24h in the absence of antibiotics, Emax, Lee 1599 / Emax,Rif is the 
maximal effect of Lee 1599/ RIF, EC50,Lee 1599 /EC50,RIF is the effective concentration of 
Lee 1599/RIF to achieve 50% of maximal effect, CLee 1599/CRIF is the concentration of Lee 
1599/RIF.  
 
 Volume under the plane (VUP) for both observed and predicted effect was 
calculated using MATLAB 8.2. The interaction index (II) is the ratio of 
VUPobserved/VUPpredicted and it defines the pharmacodynamic interaction between 
two agents as synergism (II<1) and antagonism (II>1). An II around 1 suggests no 
interaction, i.e. an additive effect. 
 
 
 
 
 
 75 
In vitro PK/PD model 
 
 The dynamic time kill curves for different doses of Lee 1599 and RIF were 
established using a modified version of our in vitro PK/PD model. As described 
previously, [39] the in vitro PK/PD model system consists of a two-armed, water jacketed 
flask (1965 series spinner flask, Bellco Glass, Vineland, NJ) as depicted in Figure 4-1. A 
filter unit attached to a hollow steel tube was introduced into the system. The filter unit 
contained a prefilter (5μm, Millipore, Billerica, MA) and filter membrane (0.22μm, 
Millipore, Billerica, MA) to prevent leakage of bacteria during the dilution process. The 
other end of the tube was connected to plastic tubing (PharMed tubing, Cole-Parmer, 
Vernon Hills, IL) from which the media was withdrawn continuously at a defined flow 
rate using a peristaltic pump (Masterflex L/S, Cole-Parmer, Vernon Hills, IL). The flask 
was placed on a magnetic stirrer for homogeneity of the culture and preventing 
membrane blockage. The temperature of the system was set at 37oC with the help of a 
thermostatic water bath attached to the water-jacketed flask. One arm of the flask was 
connected by plastic tubing to the fresh sterile media reservoir and the other arm was 
used for dosing and repeated sampling.  
 
 For simultaneously generating the concentration-time profiles for two antibiotics, 
additional components were added to the model utilized for a single drug treatment. The 
additional component is a supplementing compartment that contains the second 
administered drug. As shown in Figure 5-1, one of the sidearm of the flask is connected 
to the reservoir containing sterile medium and the supplementing compartment. The drug 
having the higher clearance was administered as bolus dose from the side arm. The flow 
rates (F) of the inlet and outlet in the central compartment and supplementing 
compartment were computed based on equations described by Jürg Blaser [116]. The 
individual values of each flow rate in and out of supplementing and central compartment 
are shown in Figure 5-1. A supplementing reservoir contains media with the drug with 
the slower clearance. The change in concentration per unit time will be same in both the 
compartments. Thus, the volume of supplementing compartment and flow rate is 
calculated as: 
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 Where, Vs is volume of media in the supplementing compartment; CLA and CLB 
are the clearance of Drug A and B; Vc is volume of media in the supplementing 
compartment (55mL); F is the flow rate of media and t1/2 of drug was  obtained from in 
vivo studies in rats. The t1/2 of Lee 1599 was experimentally determined and RIF was 
obtained from literature [117].  
 
 The combination tested in this experiment was Lee 1599 and rifampicin. Lee 
1599 (Drug A) has a higher clearance than rifampicin (Drug B). The in vitro set up is 
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Figure 5-1. A representation of in vitro PK/PD model set up for dynamic time-kill 
studies. 
 
Notes: Drug A is Lee 1599 and Drug B is RIF. 
  
 77 
assembled in a biosafety cabinet in a sterile environment. The flask and the tubes are 
cleaned and sterilized by autoclaving before starting every experiment. 
 
 
Time kill curves for Lee 1599 
 
 M. bovis BCG was used as a test organism for evaluating the effect of drug in 
vitro model. The organism was grown to early logarithmic phase (O.D.600 0.4-0.7) in 
Middlebrook 7H9 medium. This actively growing bacteria was used as an inoculum for 
the in vitro model making the final density of the culture as 106 CFU/mL. 
 
 Samples of 200μL were collected every 12h from the central compartment flask 
with volume replacement containing fresh media. The samples were centrifuged at 
10,000 rpm for 10min at 37oC. The formed pellets were collected and re-suspended in 
antibiotic-free media. This step was to ensure that there is no drug carry-over effect. The 
samples were serially diluted and the dilutions were plated on 7H11 agar plates in 
duplicate. To check if there are any resistant colonies forming bacteria, the samples were 
also plated on agar plates with 1X, 2X and 4X MIC of each drug. The agar plates were 
incubated for 21days at 37oC. The efficacy of Lee 1599 was characterized by measuring 
the reduction in number of viable bacteria, in terms of CFU/mL. There was a control arm 
included in the study to determine the bacterial growth in absence of drug. 
 
 
In vivo efficacy studies 
 
 The results of the checkerboard assay, the response surface assay and the in vitro 
PKPD model were compared to results of in vivo efficacy studies for Lee 1599 and RIF. 
The methodology for the animal studies and the endpoint analysis are described as Model 
2 and 3 in a previous study [81]. The formulation for Lee 1599 was freshly prepared 
using 5 parts of USP Multiple Electrolytes Solution (PlasmaLyte, Baxter Healthcare 
Corp., Deefield, IL) and 1 part sterile  deionized water. RIF was ground to a fine powder 
using mortar and pestle, and sterile deionized water was added incrementally to the total 
volume. The formulation was stored at 4oC until required. Lee 1599 was administered 
subcutaneously at 200mg/kg QD and RIF was administered orally at 10mg/kg QD. For 
the combination studies, both drugs were administered simultaneously at the same doses 
and route of administration as given in monotherapy. 
 
 
Results 
 
 
Checkerboard assay 
 
 The drug aliquots were stable at the beginning of experiments and this was 
confirmed using LC-MS analysis. In the checkerboard assay, the positive control wells 
that did not contain any drug showed bacterial growth at the end of the incubation period 
 78 
as expected. The MIC of Lee 1599 was found to be 0.8μg/mL, which is consistent with 
the MIC determination that had been performed during the initial screening of the 
spectinamide series. The MIC of Lee 1599 was found to be similar for M. bovis BCG and 
M. tb. The FICI score for Lee 1599 was 0.375 as shown in Table 5-1. The MIC of both, 
RIF and Lee 1599 was significantly reduced in the presence of each other. As the FICI 
score for this tested combinations is below 0.5 it suggests that RIF has a synergistic 
interaction with Lee 1599. 
 
 
Response surface assay 
 
 Lee 1599 and RIF exhibited similar concentration-killing profiles in pilot studies 
as shown in Figure 5-2. The optimal concentration was found to be approximately 
6.4μg/mL for 1599 and 1.6μg/mL for RIF. There was no ceiling effect observed for both 
of the drugs. A reasonable model fit was obtained for Lee 1599 (r2=0.992) and RIF 
(r2=0.996) for the applied inhibitory sigmoid Emax-model based on model diagnostics. 
The concentrations for capturing the most precise parameter estimates describing the 
killing effect for Lee 1599 were found at 0.04, 0.4, 0.8, 1.6, 3.2 and 6.4μg/mL, whereas 
the concentrations to obtain parameter estimates for RIF were 0.02, 0.2, 0.4, 0.8 and 
1.6μg/mL. 
 
 To analyze the pharmacodynamics interaction between Lee 1599 and RIF, we 
plotted the combined effect of both the agents using a three-dimensional response surface 
approach (Figure 5-3). A three dimensional plot of bacterial count vs. concentration was 
plotted with Lee 1599 concentration on the x-axis, RIF concentration on the y-axis and 
bacterial count in Log CFU on the z-axis. The “null interaction” surface was constructed 
in a separate plot using a set of points representing model predicted additive effect of 
combinations of Lee 1599 and RIF and is shown in Figure 5-4. In all different sets of 
concentrations of the compounds in combination, an increased killing effect was seen as 
compared to either drug alone at the same concentration. The killing effect by one agent 
was supplemented by the presence of the other agent. The volumes under the plane 
(VUP) for the observed effect and model predicted effect as shown in Table 5-2 are 
274.84 and 271.86 log CFU μg2/mL3. The interaction index calculated based on the 
obtained VUPs was found to be 1.01 indicating an additive effect exerted by the 
combination of Lee 1599 and RIF. 
 
 
In vitro PK/PD model for combination agents 
 
 For the in vitro PK/PD model, three different dosing regimens for Lee 1599 and 
two for RIF were selected to be investigated in combination experiments: 100mg/kg QD, 
10mg/kg QD and 1mg/kg QD for Lee 1599 and 10mg/kg QD and 0.5mg/kg QD for RIF. 
As shown in Figure 5-5, there was a marginal increase in the average bacterial killing 
when both the agents were used in combination as compared to when administered 
individually. The bacterial counts were below limit of quantification for the timepoints 
without any data points beyond 48h or 72h in the time-kill curves. The bacterial counts at 
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Table 5-1. Checkerboard assay results to determine pharmacodynamic 
interaction between Lee 1599 and RIF. 
 
Agent MIC of 
agent alone 
(μg/mL) 
MIC in 
presence of 
Lee 1599 
(μg/mL) 
MIC of Lee 
1599 in 
presence of 
agent (μg/mL) 
FICI 
score 
Indication 
Rifampicin 0.002 0.0005 0.1 0.375 Synergy 
 
Note: The MIC of Lee 1599 alone is 0.8μg/mL. 
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Figure 5-2. Model fits of bacterial burden at 24h in static time kill studies for Lee 
1599 (A) and RIF (B) to obtain the parameter estimates such as E0, Emax and EC50. 
(A) 
(B) 
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Figure 5-3. Observed effect of combination agent Lee 1599 and RIF. 
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Figure 5-4. Model predicted effect of the combination compound Lee 1599 and 
RIF. 
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Table 5-2. Results of three dimensional surface response assay. 
 
Model VUP 
value 
Ratio 
(VUPobs/VUPpred) 
Indication 
Observed effect 274.84 1.01 Additive effect 
Model predicted effect 271.86 
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Figure 5-5. In vitro PK/PD dynamic time kill study for Lee 1599, RIF and its 
combination with different doses.  
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48h for all the treatment groups were arbitrarily selected for quantitative comparison as 
shown in Figure 5-6. At higher doses of 100mg/kg Lee 1599 and 10mg/kg RIF, there is 
an average of 4 log CFU/mL reduction in bacterial counts when the agents are 
administered in combination as compared to 2.44 log CFU/mL by Lee 1599 alone or 3 
log CFU/mL by RIF alone. Similarly, an approximate 4 log CFU/mL bacterial killing 
was observed when 10mg/kg Lee 1599 was co-administered with 10mg/kg RIF as 
compared to 1.73 log CFU/mL killing with 10mg/kg Lee 1599 alone. The efficacy 
observed with both dose group including the higher RIF dose (100mg/kg Lee 1599 + 
10mg/kg RIF and 10mg/kg Lee 1599 + 10mg/kg RIF) were almost identical. This can be 
possibly due to a ceiling effect in the killing pattern by Lee 1599 when given with high 
doses of RIF. 
 
 At much lower doses, an average of 2.5 log CFU/mL bacterial reduction was 
observed with 1mg/kg 1599 + 0.5mg/kg RIF. A dose of 1mg/kg Lee 1599 did not show 
any evidence for sterilizing activity. However, the same dose when co-administered with 
0.5mg/kg RIF could improve bacterial killing in contrast to individual Lee 1599 dose at 
48h and 72h (p < 0.05). All three sets of combination doses showed an increased bacterial 
killing when both the agents were administered in combination. This is an indication of 
an additive effect of both the anti-bacterial agents in combination. 
 
 
In vivo studies 
 
 The results of our pharmacodynamic interaction assays of the Lee 1599-RIF 
combination were subsequently compared to in vivo efficacy results after 4 weeks of 
treatment in an acute M. tb infection model in mice performed by our collaborators, Dr. 
Anne Lenaerts and her group at Colorado State University. The studies were carried out 
in two different groups: A high dose aerosol (HDA) and low dose aerosol (LDA) 
infection with 200mg/kg QD Lee 1599 (subcutaneously) and 10mg/kg QD RIF (oral) 
administered as shown in Figure 5-7. The HDA group was inoculated with 3.5 log CFU 
per mouse and LDA group was inoculated with 2 log CFU per mouse. For the HDA 
group, the observed bacterial reduction was 2.14, 1.08 and 2.97 log CFU with Lee 1599, 
RIF and combination of both drugs, respectively. The expected combined effect of Lee 
1599 and RIF assuming there is no interaction between the two drugs can be calculated as 
3.22 log CFU. Similarly, for the LDA group, the observed effect with combination was 
2.79 log CFU and theoretical summation was 2.84 log CFU. The close proximity of the 
observed and the expected value for efficacy of the combination regimens suggests that 
Lee 1599 and RIF have an additive effect when given in combination. 
 
 
Discussion 
 
 Spectinamide Lee 1599 has excellent anti-TB activity both in vitro and in vivo 
and has demonstrated potency against MDR- and XDR-TB strains obtained from several 
clinical isolates. It is a well-known fact that TB therapeutic regimen require a 
combination of multiple anti-TB drugs. It is evident that eventually every drug against 
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Figure 5-6. The bacterial log reduction with different doses using an in vitro 
PK/PD dynamic time kill experiment. 
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Figure 5-7. In vivo efficacy trial data showing bacterial burden reduction (log 
CFU/mL) in the lungs of M. tb infected mice, N=6 for Lee 1599 and Lee 1599+RIF, 
N=5 for RIF.  
 
Notes: Lee 1599 was administered subcutaneously at 200mg/kg and RIF was dosed 
orally at 10mg/kg. The results are significant for all dose groups at p<0.05 by pairwise 
multiple comparison procedures (Tukey test). 
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TB will be co-administered with other anti-TB drugs [21]. In our ongoing research 
studies, we hypothesized an increase in pharmacodynamic effect when spectinamide Lee 
1599 is co-administered with another established anti-TB drug and that this increase in in 
vivo effect can be predicted by adequate in vitro assays. The model drug selected for the 
purpose of our study was RIF, a first-line antibiotic used for TB therapy. The change in 
pharmacodynamic effect upon co-administration of two drugs is frequently determined 
using techniques such as the checkerboard assay, the E-test and time-kill curves both in 
vitro and in vivo [118, 119]. We applied two of these methods for primary screening: the 
checkerboard assay and the three dimensional surface response assay. As shown by our 
results, there is a clear disconnect between the outcomes of these two methods as shown 
in Table 5-3. The checkerboard assay suggested a synergistic interaction between Lee 
1599 and RIF. However, the three dimensional surface response assays indicated an 
additive effect between the two compounds. 
 
 The primary reason for the difference between these two methods is likely rooted 
in the underlying principles of both methods. The basis of null interaction for the FICI 
score derived from the checkerboard assay is the Loewe additivity method. However, 
there are several pitfalls associated with the checkerboard assay: (1) The initial bacterial 
load for testing interactions is much lower (OD600 0.01 or 105 CFU/mL) than what is 
observed in in vivo studies or in patients [120, 121]. (2) The endpoint is often based on 
visual inspection and very subjective, increasing the possibility of erroneous results. 
Since, it follows a 2-fold dilution technique; there is a high possibility of one-well errors. 
Though this error may be undervalued assuming a miniscule marginal error, the error is 
magnified and the extent of allowance increases at higher dilutions [122]. (3) Moreover, 
there are various methods to calculate the FICI index using the checkerboard assay and 
there has been variability reported with different methods of interpretation of 
checkerboard synergy testing [123].  
 
 To overcome these limitations, we advanced with a quantitative, parametric three 
dimensional surface response approach proposed by Tam et al. The surface response 
approach has several advantages over the checkerboard assay: (1) The endpoint is the 
quantification of bacterial counts on agar plates as opposed to visual inspection. (2) The 
initial number of bacteria pre-dose, approximately 107-108 CFU/mL, is much higher 
relative to the checkerboard assay and comparable to in vivo mouse infection models. (3) 
The bacterial inoculum is in higher volumes of media providing a more conducive 
environment with fresh nutrients for bacterial growth. (4) The difference in bacterial 
counts in dosing and control groups after 24h of incubation normalizes the bacterial 
reduction thus providing us with a measure for extent of bacterial killing. Based on these 
facts, the indication of combination effects from the response surface assay seems to be 
more reliable compared to the checkerboard assay based on the above mentioned 
rationales.  
 
 It is obligatory to validate the results obtained from two different screening 
assays, particularly if the two applied methodologies provide discordant results as in our 
study. We therefore performed an in vitro PK/PD model based dynamic time-kill study as 
opposed to static time kill studies to validate the preliminary findings and confirm the  
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Table 5-3. Summary of results of pharmacodynamics interactions from different 
methods. 
 
Method Indication 
Checkerboard assay Synergy 
3D surface response assay Additive effect 
Dynamic time kill curves Additive effect 
In vivo mouse studies Additive effect 
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authenticity of the above mentioned assays. The in vitro PK/PD model based time-kill 
curves were performed under dynamic conditions and take into account the fluctuating 
concentration of drug over time mimicking the pharmacokinetic conditions observed in 
vivo. Although the hollow fiber infection model (HFIM) is now used by an increasing 
number of research groups for this purpose, our previously used in vitro PK/PD model 
has several advantages over the use of HFIM if used for the compound screening. Some 
of the major limitations of the HFIM is non-specific drug binding (especially highly 
lipophilic compounds) to the hollow fiber capillaries producing misleading results, 
relatively high cost and complex operation. Our in vitro model uses a substantially easier 
setup, and can be sterilized and reused between two cycles of different studies. This 
makes the in vitro model very cost-effective and ideal for use in exploratory trials to test 
multiple dose and dosing regimens [39].  
 
 The results from the time-kill curves experiments indicate a moderate increase in 
bacterial reduction with combination treatment as compared to monotherapy. The net 
bacterial reduction with combination is approximately the algebraic sum of bacterial 
reduction caused by the two agents during monotherapy. Thus, the time-kill results 
indicated an additive effect between Lee 1599 and RIF. To compare the efficacy among 
the treatment regimens, we selected the 48h timepoint as the bacterial counts were below 
the quantification limit at later timepoints in the Lee 1599 100mg/kg QD and RIF 
10mg/kg QD dose groups. The bacterial killing increases with increasing doses of Lee 
1599 or RIF alone, which is expected based on their previously observed non-linear dose 
response relationships. The combined effect at low doses of Lee 1599 1mg/kg and RIF 
0.5mg/kg was marginally higher than RIF 0.5mg/kg. However, when higher doses for 
both Lee 1599 and RIF are co-administered there is a substantial increase in the reduction 
of bacterial counts. Theoretically, the bacterial reduction for the Lee 1599 100mg/kg + 
RIF 10mg/kg group should be higher than Lee 1599 10mg/kg + RIF 10mg/kg group. The 
observed effect for both groups, Lee 1599 100mg/kg+RIF 10mg/kg and Lee 1599 
10mg/kg + RIF 10mg/kg group, however, showed similar efficacy, that was significantly 
higher than for the groups treated with Lee 1599 alone (p<0.05). This clearly suggests 
that doses of 10mg/kg and 100mg/kg of Lee 1599 when given in combination with 
10mg/kg RIF have the same efficacy possibly due to a ceiling effect. 
 
 There is always experimental variability associated with individual data points. 
The method of using a specific time point to compare the efficacy of different dose group 
as we applied can be erroneous, as it does not capture the cumulative effect of the 
treatment. To overcome this limitation, we calculated the area-under the curve (AUC0-t) 
for the individual time-kill curves to establish a cumulative measure of the overall effect. 
As the time-kill experiments were terminated at different time points, we determined 
AUC0-48 for all time-kill curves and normalized them with the control group. The 
percentages of AUC0-48 ratios were calculated to compare different groups as shown in 
Table 5-4. The higher the percentages, the higher the killing. The %ratios were larger for 
combination therapy as compared to monotherapy. The %ratios for Lee 1599 100mg/kg + 
RIF 10mg/kg was larger than Lee 1599 10mg/kg + RIF 10mg/kg indicating more 
bacterial kill for the former group. Also, at lower doses (Figure 5-8), the %ratio for Lee 
1599 1mg/kg + RIF 0.5mg/kg group was larger than the individual Lee 1599 and RIF  
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Table 5-4. Comparison of %AUC ratios (the %AUC were normalized with AUC 
of control group). 
 
Group %AUC ratio 
Lee 1599 100mg/kg + RIF 10mg/kg 94.1 
Lee 1599 10mg/kg + RIF 10mg/kg 91.7 
Lee 1599 100mg/kg  93.9 
Lee 1599 10mg/kg  86.1 
RIF 10mg/kg 84.5 
Lee 1599 1mg/kg + RIF 0.5mg/kg 85.9 
RIF 0.5mg/kg 74.9 
Lee 1599 1mg/kg 68.8 
Control   0.0 
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Figure 5-8. Comparison of %AUC ratios after the %AUC were normalized with 
AUC of control group indicating higher the %AUC ratio, greater the bacterial 
killing. 
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treatment arms. The enhanced killing in the combination group suggests an additive 
effect of both the agents. Thus, the AUC0-t ratios may be a better estimate for comparison 
of kill curves than a point estimate as it captures the dynamic range of the bacterial time-
kill effect. 
 
 The above in vitro results are corroborated by in vivo findings suggesting a 
additive effect between Lee 1599 and RIF. The in vivo studies were performed using 
different bacterial loads (HDA and LDA bacterial burden) for treatment. There is no 
“gold standard” definition of synergy observed under in vitro or in vivo conditions. Of the 
many definitions reported in the literature, synergy is commonly defined as ≥ 2 log 
CFU/mL reduction by combination as compared to single therapy [124, 125]. Based on 
this assessment, we interpreted the in vivo results to be an additive effect. However, these 
definitions of synergy are not necessarily translatable to clinical scenarios where the 
endpoint of treatment is an improvement in the patient’s condition. It is challenging to 
identify an additive effect or synergistic effect under clinical conditions as one can 
usually not quantify bacterial counts in patients. The primary application of these drug 
interaction characteristics determined under preclinical conditions is to adjust the dose 
and dosing regimen for the combination therapy and balancing the efficacy profile of the 
drugs without imparting any toxicity to the patient. In view of these considerations, 
drawing a line between additive effect and synergy at the preclinical stage may not give 
any edge for dose optimization in the clinic. Hence, the purpose of the drug interaction 
assays should focus on whether the combination is more efficacious or less toxic as 
compared to single dose treatment. 
 
 
Conclusions 
 
 In summary, it is crucial to carry out in vitro experiments on pharmacodynamic 
interactions for antibiotics early during the preclinical drug development phase to test 
potential interactions between two or more molecules. The results from the checkerboard 
assay or any other qualitative analysis assay should be used with caution. It is advised to 
confirm the results with quantitative methods such as three dimensional surface response 
assay, dynamic time kill curve experiments or in vivo studies to get precise information 
about the drug interaction in question. Our studies show that the preclinical drug 
development process can be hindered or misguided if decisions are based on only one 
qualitative assay. In addition, the purpose of the drug interaction assays should focus on 
whether the combination is more efficacious or less toxic as compared to single dose 
treatment rather than trying to decipher between additivity and synergism.  
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CHAPTER 6.    SUMMARY 
 
 
 The number of resistant strains of M. tb that have increased at an alarming rate 
has convinced researchers to focus on the discovery of new anti-tuberculosis drugs to 
combat this pandemic. To contribute to solutions for this problem, our research group 
discovered a novel series of anti-tuberculosis agents called spectinamides, semi-synthetic 
analogs of spectinomycin. Spectinamides are potent inhibitors of mycobacterial 
ribosomes and overcomes efflux mediated drug resistance in M. tb. Multiple of the 
compounds in the spectinamide series have shown an excellent in vitro activity and 
acceptable drug-like properties, thus making them excellent preclinical drug candidates. 
We hypothesized that a pharmacometrics-directed quantitative approach for integrated 
PK/PD characterization can guide the selection of lead candidate compounds and is more 
predictive of in vivo efficacy than some qualitative of semi-quantitative standard 
approaches. 
 
 The screening for potential lead drug candidates included multiple experiments to 
determine the pharmacokinetic parameters. In vitro screening demonstrated that 
spectinamides have low plasma protein binding and are stable against hepatic microsomal 
activity. The pharmacokinetics studies in rats revealed that renal excretion is the major 
route of elimination for most spectinamides. This route of elimination suggests that there 
is a low potential for drug-drug interactions during combination pharmacotherapy as seen 
with agents that undergo extensive hepatic metabolism. Because spectinamides are highly 
hydrophilic, distribute well in aqueous distribution spaces, and show low plasma protein 
binding, they are advantageous as therapeutic candidates over other new anti-TB agents 
where most tend to be lipophilic and have high plasma protein binding. This results in 
spectinamides being able to target bacterial subpopulations that are unreachable by more 
lipophilic compounds. 
 
 An important aspect in the safety of novel drug candidates is their biodistribution 
and potential accumulation in tissues. On the other hand, intracellular uptake into 
macrophages is a prerequisite for antibiotic activity against M. tb residing inside infected 
macrophages. Our quantitative macrophage uptake studies showed that Lee 1329, 
Lee1445 and Lee 1599 had significantly higher macrophage uptake than spectinomycin 
and streptomycin.  
 
 The biodistribution of spectinamides was determined using a tritium labelled Lee 
1329. About 70% of administered radioactivity was recovered in urine and 12.6% in 
feces, with a total mass balance of 84.7%. Total radioactivity showed similar activity-
time profiles for the first 2h after I.V. administration. Deviation at later time points 
suggests formation of circulating metabolites with longer half-life than the parent drug. 
Cmax after the 1st dose and the 8th dose is similar: 3.39μCi/mL and 3.55μCi/mL, 
suggesting no relevant accumulation of parent drug and metabolites. The activity of 
radiolabel was 3 times higher in lungs and spleen as compared to whole blood, 
suggesting good tissue penetration of Lee 1329. The results support the earlier findings 
that the major elimination pathway for Lee 1329 is renal excretion and that the compound 
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accumulates neither in blood nor in tissues during multiple dosing with a BID regimen in 
rats, which is an important aspect in the safety profile of spectinamides. 
 
 The minimum inhibitory concentration (MIC) is one of the key pharmacodynamic 
parameters used to compare and differentiate drug candidates. However, point estimates 
of pharmacodynamic activity such as MIC do not take into account the dynamic 
interaction between bacteria and fluctuating exposure to unbound drug during dosing in 
vivo. We thus applied an in vitro PK/PD model system to establish the quantitative 
interaction between bacterial growth and time-varying drug concentration for the 
emerging lead Lee 1599. The obtained results were used to identify the optimal PK/PD 
index driving Lee 1599’s efficacy, and to perform model-based numerical simulations to 
determine appropriate dosing regimens for further in vivo efficacy trials. The results 
indicate that Lee 1599 exhibits a dose-dependent bactericidal effect. Lee 1599 showed up 
to 4-log reductions in bacterial counts at 100mg QD dosing. The PK/PD indices 
demonstrate that Lee 1599 elicits a concentration- and time-dependent killing with 
AUC/MIC as the optimal index. The in vitro PK/PD simulated profile suggests that 
higher doses with shorter dosing intervals may demonstrate optimal efficacy in vivo. 
 
 With an increasing frequency of mycobacterial resistant strains, there is an 
emerging need for robust and effective combination therapy. The conventional screening 
method for determining pharmacodynamic drug interactions using the Checkerboard 
assay depends on a subjective endpoint of growth inhibition and fails to provide any 
information on extent of bacterial growth or kill over time. We applied parametric 
approach to quantitatively assess the pharmacodynamics drug interaction between the 
lead candidate compound Lee 1599 and rifampicin. The three dimensional surface 
response assay demonstrated that there is an additive effect between both agents as 
opposed to the checkerboard assay, which showed synergism between these agents. The 
results of the surface response assay were validated using an in vitro PK/PD model for 
combination agents and in vivo efficacy trials. These results suggest that the quantitative 
response surface assay may be a screening tool for drug interactions that is more 
predictable of in vivo interactions than the traditional checkerboard assay. In addition, the 
additive effect between Lee 1599 and rifampicin suggest that a combination therapy may 
warrant optimal efficacy results at lower doses than single drug therapy of either drug.   
 
 In conclusion, we have successfully supported the further development of 
spectinamides using a pharmacometric approach. We have contributed to the selection of 
lead candidate compounds such as Lee 1599 using quantitative PK/PD approaches in its 
pre-clinical development. The application of PK/PD knowledge is essential for 
translating the in vitro screening assay findings to the in vivo stage. The results of the 
above studies may serve to illustrate the optimization of anti-infective agents in the early 
drug discovery and development. 
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